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ABSTRACT 
Infectious bursal disease virus (IBDV) is a non-enveloped Birnavirus which infects 
the immature antibody producing B-cells of the bursa of Fabricius in young chickens. 
The virus causes infectious bursal disease (IBD) which is highly contagious and 
immunosuppressive. A compromised immune system in infected chickens leaves 
them susceptible to other opportunistic pathogens and as a result increases their 
mortality rate. Major economic losses in the commercial poultry industry are 
subsequently experienced in affected regions. Currently vaccines are used to 
control IBDV infection, however, their efficacy is affected by factors such as the 
presence of maternally derived antibodies in young chickens which reduces vaccine 
load, the continuous emergence of new virulent IBDV strains and bursal atrophy 
caused by some vaccines. It is therefore important to consider new ways of 
controlling the virus such as targeting specific stages in the virus life cycle. Since 
virus attachment to host cell receptor(s) is the most crucial step in the virus life 
cycle, developing novel antiviral agents which prevent viral entry represents a good 
alternative strategy for IBDV control. Identification of receptor binding proteins and 
receptors of host cell membranes is required for antiviral development. The receptor 
binding protein and outer capsid of IBDV is VP2, however, the receptor(s) utilised by 
IBDV to gain entry into host cells have not been conclusively identified.  
 
Recombinant VP2 was used to identify possible IBDV receptor(s) on bursal plasma 
membranes using a virus overlay protein binding assay (VOPBA) and affinity 
chromatography. Therefore, VP2 was heterologously expressed in an Escherichia 
coli and a Pichia pastoris expression system as a 64 kDa fusion protein and a 
47 kDa protein respectively. In addition, both systems expressed VP2 as high 
molecular mass proteins which were confirmed by electro-elution and western 
blotting. Although purification of VP2 expressed in the E. coli system was a 
challenge because VP2 expressed as inclusion bodies, polyclonal chicken anti-VP2 
antibodies were produced using VP2 expressed in this system. Purification of VP2 
expressed in P. pastoris was easier and produced a greater yield of VP2 which was 
used to produce a VP2-coupled affinity matrix for the purification of chicken anti-VP2 
antibodies and for the purification of VP2-binding proteins of the bursal plasma 
membrane. Moreover, peptides were selected from the VP2 amino acid sequence 
and use to raise polyclonal chicken anti-VP2 peptide antibodies for comparative 
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identification against chicken anti-VP2 antibodies of possible IBDV receptor(s). Two 
IBDV VP2-binding proteins with molecular masses of 70 and 32 kDa of the bursal 
plasma membrane were identified in a VOPBA using recombinant VP2 or IBDV and 
chicken anti-VP2 antibodies. In addition to the VOPBA, four IBDV VP2-binding 
proteins with molecular masses of 70, 60, 45 and 32 kDa were affinity purified on a 
VP2-coupled affinity matrix. Analysis of the affinity purified proteins by mass 
spectrometry identified five proteins which share common peptides which include, 
the Ig-gamma chain and Ig-lambda chain of Gallus gallus, outer major protein of 
Serratia marcescens, the 60 kDa chaperonin of Pseudomonas fluorescens and 
elongation factor-Tu of Yersinia pestis. The results strongly suggest that an Ig-
receptor like protein may form part of the IBDV receptor, however, much further 
work is required in order to establish whether the chicken homologues of the 
identified bacterial sequences are part of the putative bursal receptor. It is believed 
that the bacterial proteins contain common peptides with chicken proteins of the 
chicken genome which has not been fully annotated as yet. Taken together, this 
study successfully used VP2 to identify possible IBDV receptor(s) on bursal plasma 
membranes which could ultimately lead to the development of antiviral agents 
targeted at IBDV entry. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 INTRODUCTION 
Infectious bursal disease virus (IBDV) is a Birnavirus which mostly affects young 
chickens, causing infectious bursal disease (IBD) (Kibenge et al., 1988). The 
disease is highly contagious and was first discovered in 1960 in a town called 
Gumboro in Delaware, USA (Cosgrove, 1962) and is therefore referred to as 
Gumboro disease (Muller et al., 2003). IBD has had a significant economic impact 
on the poultry industry (Muller et al., 2003, Lee et al., 2006a) and has spread to 
many countries in the world, including South Africa (Horner et al., 1994, Vukea et 
al., 2014). 
 
The virus infects immature B-cells in the bursa of Fabricius of young chickens and 
replicates in the cytoplasm of infected cells (Kibenge et al., 1988, van den Berg et 
al., 2000, Muller et al., 2003). This leads to the depletion of the B-lymphocytes, 
which in turn results in an immunosuppression. Clinical signs of the disease are 
observed in chickens between 3-6 weeks old (Muller et al., 2003) and include ruffled 
feathers, watery diarrhoea, trembling, and severe prostration (Cosgrove, 1962). 
Sub-clinical effects include immunosuppression, which leaves chickens susceptible 
to other pathogens and mortality levels increase as a result of increased frequency 
of external infections (Saif, 1991).  
 
The current control strategy for IBDV is vaccination (Muller et al., 2012). Multiple 
vaccines are currently available, but the vaccine effectiveness is often reduced due 
to maternally acquired antibodies (Corley and Giambrone, 2002). These antibodies 
have been shown to neutralise IBDV vaccines and therefore decrease the vaccine 
virus load, which is required to achieve immunity (Corley et al., 2002, van den Berg 
et al., 2004, Zhou et al., 2010). Vaccines have been shown to cause moderate 
bursal atrophy (Snyder, 1990, Zhou et al., 2010) such as Nobilis® Gumboro inac 
(Intervet International B.V., Egypt), an inactive IBDV vaccine. Therefore, there is still 
a need to explore other methods to control or prevent the disease. 
 
Viral infections can be controlled through anti-viral agents, which target crucial 
processes in the viral life cycle. One such process for IBDV is viral entry into host 
cells during infection. Such drugs have been developed for HIV entry into the host 
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cell (Kilby and Eron, 2003). Due to the existence of new variant strains of HIV, 
targeting viral entry is a good approach to prevent infection (Kilby and Eron, 2003). 
Success has been achieved in HIV-receptor drug development and one of the drug 
compounds, PRO 542, was found to be “well tolerated” and its antiviral activity was 
reported in both adults (Jacobson et al., 2000) and children (Shearer et al., 2000). 
One of the first steps in understanding viral entry is identification of host receptor 
proteins utilised. 
 
Bursal membrane receptor proteins which IBDV uses to gain entry have not been 
conclusively identified. Thus far, chicken heat shock protein 90 (cHsp90) has been 
identified as a constituent of the bursal membrane receptor through the use of whole 
virus and subviral particles (SVP) in different cell lines (Lin et al., 2007, Zhu et al., 
2008). The aim of the present study was to use the outer capsid protein, VP2 which 
has also been shown to be the receptor binding protein (Yip et al., 2007) to identify 
the receptors on the bursal membranes. 
 
 
1.2 INFECTIOUS BURSAL DISEASE VIRUS 
1.2.1 Taxonomy and Structure 
IBDV belongs to the Avibirnavirus genus of the Birnaviridae family which consists of 
icosahedral non-enveloped viruses (Dobos et al., 1979). The family includes 
infectious pancreatic necrosis virus (IPNV) of young salmonid fish (Cohen et al., 
1973), Drosophila X virus (DXV) of Culicoides spp. in the genus Entomobirnavirus 
(Dobos et al., 1979, Teninges et al., 1979), blotched snakehead virus (BSNV) (Da 
Costa et al., 2003), Tellina-1 virus (TV-1) (Nobiron et al., 2008)  and oyster virus 
(OV) of bivalve molluscs in the genus Aquabirnavirus and the Espirito Santo virus 
(ESV) (Vancini et al., 2012). The IBDV icosahedron has a single-shelled capsid and 
is about 60 nm in diameter (Dobos et al., 1979, Bottcher et al., 1997). The 
icosohedral structure is based on a T=13 lattice (Figure 1.1A and B) with the outer 
surface of the capsid formed by trimeric subunits of VP2 (Bottcher et al., 1997, 
Coulibaly et al., 2005).  
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Figure 1.1 The IBDV virion. (A) Electron micrograph of IBDV particles in an unstained, 
frozen, hydrated preparation. Arrowheads point to IBDV particles. Bar, 100 nm (B) Three-
dimensional structure of a frozen hydrated IBDV particle at 2 nm resolution. The two, three, 
five and six fold axes are marked to indicate the T=13 architecture, (Bottcher et al., 1997). 
 
The birnavirus genome is made up of two segments of dsRNA, segment A and 
segment B. Segment A is 3.4 kb in size and has two open reading frames (ORFs), 
A1 and A2, which partially overlap (Figure 1.2). ORF A1 encodes VP5, a 17 kDa 
non-structural protein that assists in the release of the IBDV progeny (Lombardo et 
al., 2000). VP5 is a cysteine rich class 2 membrane protein which has a cytoplasmic 
N-terminus and an extracellular C-terminal domain and accumulates in the 
cytoplasm until it allows for the release of the virus (Lombardo et al., 2000). The 
larger ORF A2 codes for a 110 kDa polyprotein (NH2-pVP2-VP4-VP3-COOH) which 
is proteolytically cleaved by VP4 to yield precursor VP2 (pVP2) (Met1-Ala512; 54 
kDa), mature VP4 (Ala513-Ala755, 28 kDa) and VP3 (Ala756-Glu1012, 32 kDa) (Muller 
and Becht, 1982) (Figure 1.2). Segment B is 2.9 kb in size and codes for VP1 (90 
kDa), the RNA-dependent-RNA polymerase (RdRp) (Lombardo et al., 1999)  which 
is covalently integrated to the viral RNA as a genome-linked protein (Kibenge and 
Dhama, 1997) and is also found as a 90 kDa protein within the virion in its “free” 
form (Kibenge and Dhama, 1997). 
 
VP4 is a serine protease that uses a Ser652/Lys692 catalytic dyad which cleaves Ala-
Ala dipeptide bonds (Birghan et al., 2000, Lejal et al., 2000). VP3 is a structural 
protein which forms Y-shaped trimers on the inner capsid surface of IBDV and has a 
very basic carboxy-terminal region which is associated with the packaged viral 
RdRp, VP1 (Hudson et al., 1986, Chevalier et al., 2004). pVP2 is further cleaved to 
yield mature VP2 (Met1-Ala441, 47 kDa) (Muller and Becht, 1982) and four smaller 
structural peptides, pep46 (Phe442-Ala488), pep7a (Ala489-Ala494), pep7b (Ala495-
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Ala501) and pep11 (Ala502-Ala512) (Da Costa et al., 2002) (Figure 1.2). These peptides 
remain associated with the capsid (Da Costa et al., 2002) and are involved in cell 
entry by promoting disruption of host cell membranes (Chevalier et al., 2005, 
Galloux et al., 2007). Initially, the secondary processing of pVP2 into VP2 was 
hypothesised to be catalysed by VP4 protease based on the presence of the Ala-Ala 
bonds (Kibenge et al., 1988). However, Lee et al. (2004) demonstrated that the 
processing of pVP2 was observed in the absence of VP4. It was subsequently 
shown that the processing at the Ala441-Phe442 bond to release VP2 was carried out 
by the endopeptidase activity of the capsid protein VP2 involving the Ala431 residue 
(Irigoyen et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of genomic structure and polyprotein processing 
of IBDV. ORFs, proteins and peptides are depicted as rectangular boxes. Red arrows 
indicate translation while black arrows indicate cleavage products during polyprotein 
processing. N-terminal and C-terminal residues are indicated above each protein or peptide 
and the base pair numbers are indicated above Segment A to portray the overlapping ORFs.  
 
 
VP2 is a structural protein which forms trimers on the outer capsid of IBDV as 
protrusions on the surface and is the receptor binding protein (Yip et al., 2007). VP2 
is also the primary host-protective immunogen and therefore the primary target for 
vaccine development (Chen et al., 2005). The crystal structure of IBDV VP2 subviral 
particle (SVP) (T=1) has been resolved at 2.6 Å (Coulibaly et al., 2005, Garriga et 
al., 2006, Lee et al., 2006a)  and revealed the VP2 subunit folds into a jelly roll fold 
with three distinct domains; base (B), shell (S) and projection (P) (Figure 1.3A). 
Domains B and S are well conserved while domain P is highly variable (Coulibaly et 
5 
 
al., 2005, Garriga et al., 2006, Lee et al., 2006a) resulting in the continuous 
emergence of variant IBDV strains (Chen et al., 2005). All three domains take part in 
trimer formation which resembles an equilateral triangle (Figure 1.3C) with each side 
measuring 100 Å with a thickness of 25 Å (Coulibaly et al., 2005, Garriga et al., 
2006, Lee et al., 2006a). A calcium-binding site is located on the internal surface of 
the SVP (Figure 1.3B and C) and binds three pairs of symmetry-related Asp31 and 
Asp174 in domain S. The Ca2+ ion acts as a sealing element for the VP2 trimers 
(Coulibaly et al., 2005, Garriga et al., 2006, Lee et al., 2006a) by arranging the two 
Asp residues from three VP2 subunits in an octahedral geometry. In addition, an 
amphipathic α-helix is found on the C-terminus which mediates interaction between 
trimers and is important in capsid assembly (Luque et al., 2007) (Figure 1.3B and 
D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The structure of VP2 subunit and VP2 trimer formation. (A) VP2 ribbon 
structure.  The domains are coloured according  to the side bar and represent  the P domain 
in red,  the S domain in blue and the B domain in green (Coulibaly et al., 2005). (B)  Ribbon 
diagram of VP2 showing the amphipathic α-helix on the C-terminus. The three different 
domains P, S, and B are coloured orange, blue and green respectively. Additional amino 
acids of the N and C termini are shown in red. The Ca
2+ 
ion is represented as a solid sphere 
in yellow (Garriga et al., 2006). (C) VP2 trimer formation. The domains and Ca
2+ 
ion are 
depicted by the same colours as those in panel B (Garriga et al., 2006). (D) VP2 SVP ribbon 
diagram.  The domains are represented by the same colours as those in panel B and C and 
the figure is used to illustrate the position of the amphipathic α-helix (red) which connects the 
different trimers, (Garriga et al., 2006).  
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The virus is not easily adapted to cell culture and requires multiple passages 
(Hassan et al., 1996, van Loon et al., 2002). However, it was demonstrated that 
altering specific amino acids in the VP2 amino acid sequence allowed for tissue 
culture adaptation and attenuation of the virus (van Loon et al., 2002). It was 
therefore observed that VP2 contains tissue culture adaptation determinants. 
Sequence analysis determined that tissue adaptation resulted in the change of three 
amino acid residues in the VP2 amino acid sequence (Yamaguchi et al., 1996b, van 
Loon et al., 2002, Kwon and Kim, 2004). These changes included Glu253His, 
Asp279Asn and Ala284Thr (Yamaguchi et al., 1996b, Kwon and Kim, 2004). The 
three amino acid residues are located on the most exposed loops of the P domain 
which is the site of high variability referred to as the P-loop (Coulibaly et al., 2005). 
The residues are not involved in the stabilisation of the capsid or in contacts 
important for the VP2 fold but they engage directly with the cellular receptor on 
bursal membranes (Coulibaly et al., 2005). 
 
 
1.2.2 Virulence of IBDV 
Two different serotypes of IBDV are distinguished by virus neutralisation tests 
(McFerran et al., 1980). Serotype I viruses are pathogenic in chickens causing 
bursal atrophy and immunosuppression while serotype II viruses isolated from 
turkeys, fowls and ducks are non-pathogenic in chickens. Serotype I viruses are 
further grouped into four pathotypes based on their virulence, namely classical 
virulent, antigenic variant IBDV, attenuated and very virulent IBDV (vvIBDV) (Lim et 
al., 1999).  
 
The classical virulent strains were first discovered in Gumboro in 1960 (Cosgrove, 
1962). Clinical signs displayed by chicken infected with this pathotype include 
inflammation of the bursa and lymphoid necrosis which leads to immunosuppression 
and 20 to 30% mortality in specific-pathogen-free (SPF) chickens (Lim et al., 1999). 
In the mid 1980s, vaccinations were seen to fail in different parts of the world. The 
new isolates emerged due to antigenic drift rendering vaccines made against 
classical virulent IBDV ineffective to the new isolates (Jackwood and Saif, 1987, 
Snyder et al., 1992, van den Berg et al., 2000). The new IBDV strain termed 
antigenic variant IBDV causes rapid and severe bursal atrophy without showing any 
clinical signs of infection like classical virulent IBDV (Vakharia et al., 1994). 
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Therefore antigenic variant strains are recognised by their ability to escape cross-
neutralisation with antisera against classical virulent IBDV (Lim et al., 1999).  
 
Very virulent IBDV (vvIBDV) strains emerged in the late 1980s and are antigenically 
similar to classical IBDV (Cao et al., 1998b). However, vvIBDV strains have the 
ability to break through cellular immunity and is characterised by severe clinical 
signs and high mortality of up to 60-100% in SFP chickens (Lim et al., 1999). 
Clinical signs are similar to classical IBDV, but the acute phase is much more 
severe and widespread in the affected flocks (van den Berg et al., 2000). Attenuated 
IBDV is produced by adapting classical, variant or vvIBDV pathotypes to cell 
cultures such as chicken embryo fibroblast (CEF) cells, chicken bursal lymphoid 
cells and chicken embryo kidney cells through serial passages (Lim et al., 1999). 
The attenuated IBDV strain is therefore used as a live vaccine due to its reduced 
virulence (van den Berg et al., 2000). 
 
 
1.2.3 Pathogenesis and the bursa of Fabricius 
The bursa of Fabricius is the target organ for IBDV infection and is also the site for 
B-cell development in chickens (Kaufer and Weiss, 1980). During embryonic 
development the bursa starts developing from an epithelial bud in the cloacal region 
and by embryonic development day 8, B-cell precursors are first observed (Sayegh 
et al., 1999). B-cell precursors undergo productive immunoglobulin (Ig) gene 
arrangement and subsequent expression of surface Ig (sIg) (Ratcliffe, 2006). The 
sIg- cells undergo apoptosis while the sIg+ cells continue to divide in the bursal 
cortex and shortly before hatching migrate to the secondary lymphoid organs and 
blood across the bursal epithelial basement membrane (Nieminen et al., 2002). In 
chickens, 3-6 weeks of age, the bursa reaches its maximum development (van den 
Berg et al., 2000). No new B-cells are produced and therefore chickens are required 
to survive throughout adult life with these postbursal B-cells (Ratcliffe, 2006). 
 
The general route of IBDV infection is through the oral tract after which it moves into 
the gut and is transported by phagocytic macrophages to other tissues. 
Immunofluorescence studies conducted by Muller et al. (1979) detected IBDV in the 
macrophages and lymphoid cells of the cecum 4 h post infection (PI) and in the 
lymphoid cells of the duodenum and jejunum at 5 h PI. IBDV is also detected in the 
liver 5 h PI after which IBDV enters the blood stream (Muller et al., 1979). IBDV then 
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reaches the bursa at 11 h PI and spreads rapidly through bursal follicles causing 
extensive damage to the medulla and cortical regions as replication of viral particles 
take place (Tanimura and Sharma, 1997). IBDV enters the bloodstream again and is 
spread to other lymphoid tissues such as the cecal tonsils and spleen (Sharma et 
al., 2000).  
 
The acute phase of the disease lasts around 7-10 days during which the bursal 
follicles are depleted of B-cells and the bursa becomes atrophic (Sharma et al., 
2000) resulting in immunosuppression and mortality. Furthermore both cellular and 
humoral immune responses are compromised (Sharma et al., 2000). Neighbouring 
virus-free cells undergo apoptosis which is suggested to be the anti-viral mechanism 
of the host to prevent virus spread (Jungmann et al., 2001). VP2 and VP5 are the 
only two viral proteins that have been associated with apoptosis induction 
(Fernandez-Arias et al., 1997, Yao et al., 1998). The resulting effects of the virus 
vary due to different factors such as the strain of the virus and the age of the 
infected chicken. Chickens less than 2 weeks old are less susceptible as the bursa 
is still undergoing development and is therefore protected by maternally derived 
antibodies. Chickens between the ages of 3-6 weeks old are more susceptible to 
IBDV because the bursa has reached maximum development while chickens 
greater than 6 weeks seldom show clinical signs of the disease although they do 
develop antibodies against the virus (Mahgoub, 2012).  
 
It has been observed that antigenic variant IBDV strains induce bursal atrophy 
without inflammation while classical virulent strains induce a severe inflammatory 
response (Sharma et al., 1989) which leads to disease and often death (Muller et 
al., 1979). The vvIBDV strains induce the same effects as classic or antigenic 
variant except the rate of replication is greater (van den Berg et al., 2000). T-cells 
are resistant to IBDV infection (Hirai and Calnek, 1979) and have been shown to 
reduce replication during the beginning stages of infection (Rautenschlein et al., 
2002). The mechanism in which T-cells achieve this is still unknown. The T-cells, 
however, move into the bursa and reach capacity limit 7 days PI consequently 
preventing the spread of IBDV and allowing the cells to start recovering (Kim et al., 
2000, Sharma et al., 2000). 
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1.2.4 Control of IBDV infection 
IBDV is transmitted by direct contact with contaminated faecal matter, feed and 
drinking water or by indirect contact with contaminated vectors (van den Berg et al., 
2000). The virus is very resistant and persists after thorough cleaning and 
disinfection (Lukert and Hitchner, 1984). The current control strategy for IBDV is 
vaccination (Muller et al., 2012). There are currently different vaccines available on 
the market which include conventional live and inactivated IBDV, genetically live 
engineered IBDV, subunit vaccines, IBDV immune complex vaccines, DNA vaccines 
and live viral vector vaccines. 
 
Conventional live and inactivated vaccines are vaccines in which IBDV has been 
attenuated through serial passages in tissue culture, eggs or embryo-derived tissues 
and are used to mimic infection in the host target (Schijns et al., 2008, Muller et al., 
2012). Because the whole inactive virus is used as the vaccine, no additional 
adjuvant is required and the vaccine is suitable for mass administration. 
Unfortunately most commercially available conventional live vaccines are based on 
classical virulent IBDV (Muller et al., 2012) and therefore other strains such as 
vvIBDV and antigenic variant IBDV are able to escape neutralisation. The unwanted 
side-effects of conventional live inactive vaccination include reversion to virulence 
and moderate to severe bursal atrophy resulting in immunosuppression 
(Rautenschlein et al., 2005). Nobilis® Gumboro inac (Intervet International B.V., 
Egypt) and Medivac Gumboro Emulsion (Medion, Indonesia) are examples of 
inactivated vaccines currently available on the market. 
 
Genetically engineered vaccines are still undergoing development and none have 
yet reached the market. These vaccines are developed by mutating the IBDV VP2-
encoding nucleotide sequence through site-directed mutagenesis (Islam et al., 2001, 
van Loon et al., 2002, Raue et al., 2004, Noor, 2009, Muller et al., 2012). Reversion 
to virulence is frequent in this type of vaccine (Raue et al., 2004, Noor, 2009, Muller 
et al., 2012). Alternately, inter-serotypic vaccines are generated which consist of 
virulent serotype I and non-pathogenic serotype II strains as the parent viruses 
(Zierenberg et al., 2004, Muller et al., 2012). This vaccine was established as a 
possible vaccine candidate as it induced high antibody titres and did not cause 
damage in the bursa (Muller et al., 2012). 
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IBDV subunit vaccines are generally based on recombinantly expressed VP2 (Muller 
et al., 2012) as it contains the major protective neutralising epitopes of IBDV. The 
subunit vaccine is usually administered with an adjuvant or fused with a protein 
which enhances immunogenicity (Liu et al., 2005, Muller et al., 2012) such as 
chicken interleukin-2. Subunit vaccines have been reported to be expressed in E. 
coli (Rong et al., 2007), P. pastoris (Fahey et al., 1991) and the baculovirus system 
(Bayliss et al., 1991). A limiting factor for the subunit vaccine is the way in which it is 
administered which is intramuscularly. This method of administration can be 
considered time consuming and expensive especially on large poultry farms where 
additional booster immunisations are also required. 
 
Immune complex vaccines are a mixture of anti-IBDV specific antibodies obtained 
from the sera of immunised chickens and live IBD vaccine virus (Whitfill et al., 
1995). This type of vaccine is efficient in the presence of maternally derived 
antibodies (Haddad et al., 1997, Giambrone et al., 2001) and is more effective than 
live IBDV vaccines (Jeurissen et al., 1998). A comparative study done by Jeurissen 
et al. (1998) showed that an immune complex vaccine delayed virus detection for 5 
days and displayed much lower levels of bursal and splenic B-cell depletion in 
chickens (Jeurissen et al., 1998).  A major advantage of this type of vaccine is that it 
can be administered in ovo by commercial egg-injection machines (Muller et al., 
2012). A popular commercially available immune complex vaccine is Cevac 
Transmune IBD containing Winterfield 2512 strain IBDV which specifically targets 
classical or vvIBDV (Ivan et al., 2005). 
 
DNA vaccines comprise naked DNA which encodes the target gene. The vaccine 
successfully induced protection against a virulent IBDV infection (Haygreen et al., 
2006, Hsieh et al., 2010, Muller et al., 2012). Administration of the vaccine in ovo or 
at 1 day old requires booster immunisation with inactivated vaccine or vectored 
vaccine as studies report insufficient protective immunity without additional booster 
immunisations (Haygreen et al., 2006, Park et al., 2009, Muller et al., 2012). A 
limiting factor is also the method of vaccine administration which is oral through the 
use of bacteria, namely, Lactococcus lactis and E. coli. This method of 
administration has been variably successful possibly due to problems encountered 
during secretion or translocation of the expressed viral protein across bacterial cell 
walls (Li et al., 2006, Mahmood et al., 2007, Muller et al., 2012). 
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Live viral vector vaccines are genetically engineered vaccines which are made up of 
a donor gene integrated into the genome of a host vector. Immunisation of the 
genetically modified vector vaccine elicits an immune response against both the 
donor gene and the vector. VP2 induces protective immunity to IBDV and therefore 
has been expressed in multiple vector systems such as fowlpoxvirus (Heine and 
Boyle, 1993), Newcastle disease virus (Huang et al., 2004), herpesvirus of turkey 
(HVT) (Darteil et al., 1995) and Marek’s disease virus (Tsukamoto et al., 1999). 
Herpesvirus of turkey has been successfully used as a vector vaccine against 
Marek’s disease for many years (Muller et al., 2012) and has therefore been 
proposed as a vector vaccine for IBD because of its low sensitivity to maternally 
derived antibodies (Darteil et al., 1995, Tsukamoto et al., 2002, Muller et al., 2012). 
The Vectormune® HVT IBD + SB-1 vaccine which is currently on the market in some 
countries specifically targets IBD and Marek’s disease. Protection was reported 
against a challenge with vvIBDV (Le Gros et al., 2009) and antigenic variant IBDV 
(Perozo et al., 2009). The vectored vaccine demonstrated the best results compared 
to the other vaccine candidates, mainly due to its ability to escape interference from 
maternally derived antibodies (Muller et al., 2012). Meeusen et al. (2007), however, 
stated that it may be difficult to maintain the high efficacy of this vaccine due to the 
continual emergence of very virulent strains of both IBDV and Marek’s disease virus. 
 
Therefore it is noted that vaccines which are available are not proficient in 
controlling all strains of IBDV and all have many shortfalls. It is therefore critical to 
develop new strategies to help control infection by targeting a different stage in the 
virus life cycle such as viral entry which is the first step. 
 
 
1.3 VIRUS ENTRY 
A crucial step in the infectious life cycle of a virus is viral entry (Kalia and Jameel, 
2011) and the mechanism of entry is mostly based on the structure of the virus 
(Klasse et al., 1998). Entry of many enveloped viruses is well understood while entry 
of many non-enveloped viruses still remains unresolved. Enveloped virus entry 
involves attachment of virus receptor binding proteins to host cell receptors which 
mediate a succession of events followed by fusion of the viral membrane to the host 
membrane (Kalia and Jameel, 2011). Fusion of the viral membrane is either directly 
with the plasma membrane or an internalisation process into endosomes (Kalia and 
Jameel, 2011). Non-enveloped viruses do not fuse with the endosome membrane 
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as enveloped viruses do but rather disrupt the membrane to release viral nucleic 
acids (Kalia and Jameel, 2011). It is therefore important to identify the cellular 
receptors which viruses use on host cells in order to gain entry.  
 
 
1.3.1 Enveloped Virus Entry 
Enveloped viruses which target animal cells gain entry through direct fusion with the 
plasma membrane of the host cell (White et al., 1983) or through endocytosis and 
fusion with the endosomal membrane (Kalia and Jameel, 2011). Viruses which gain 
entry into host cells through fusion contain viral surface proteins called fusion 
proteins which are oligomeric integral membrane proteins that can be induced to 
structurally adopt distinct hydrophilic and hydrophobic states (Hernandez, 1996). 
They generally have common repeat regions consisting of six amino acid residues 
which mediate oligomerisation of the proteins and a hydrophobic region, termed the 
fusion peptide, which can enter the lipid bilayer of the host cell (Gaspar et al., 2001, 
Da Poian et al., 2005). Fusion is via initial receptor interaction which then triggers a 
pH dependent or independent conformational change allowing fusion of viral and 
cellular membranes (Peisajovich and Shai, 2002, Jahn et al., 2003, Kalia and 
Jameel, 2011). Enveloped viruses of the Paramyxoviridae family, which include the 
measles virus (Table 1.1), gain entry through direct fusion with the plasma 
membrane with the use of fusion peptides (Figure 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Viruses of the Paramyxoviridae family fuse directly with the host plasma 
membrane to gain entry into host cells. The virus interacts with receptors on host cells (1) 
which triggers a conformational change allowing the viral membrane to fuse with the host cell 
membrane (2) through the use of fusion peptides and releases viral DNA into host cytoplasm 
(3), (Lee, 2010). 
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Entry of the Human immunodeficiency virus (HIV) of the Retroviridae family (Table 
1.1) involves endocytosis and pH independent fusion. Entry is initiated by the 
interaction of attachment factors with the HIV envelope glycoprotein (Env), which is 
a highly glycosylated trimer of gp120 and gp41 heterodimers. This interaction brings 
the envelope in close proximity to the viral receptor, CD4 (Table 1.1) and CCR5 co-
receptor which increases the efficiency of infection (Orloff et al., 1991, Wilen et al., 
2012). HIV attachment factors include negatively charged cell surface heparan 
sulfate proteoglycans (Saphire et al., 2001), α4β7 integrin (Arthos et al., 2008, 
Cicala et al., 2009) and dendritic cell-specific intercellular adhesion molecular 3-
grabbing non-integrin (DC-SIGN) (Ugolini et al., 1999, Geijtenbeek et al., 2000). 
Subunit gp120 of Env then interacts with the CD4 binding site of the host cell which 
causes a rearrangement of three variable loops in gp120. This leads to the 
formation of a bridging sheet which allows the third phase of HIV entry which is co-
receptor engagement (Wilen et al., 2012). Reports have shown that HIV does not 
fuse directly with the plasma membrane as previously considered, but instead 
utilises endocytosis before fusion can completely occur (Miyauchi et al., 2009). 
Reports have shown that HIV-1 infects cells via endocytosis and envelope 
glycoprotein- and dynamin dependent fusion with endosomes (Miyauchi et al., 2009) 
(Figure 1.5). 
 
 
The Influenza virus uses a pH-dependent mechanism of entry and initiates infection 
by binding to cell surface sialic acid residues (Table 1.1) via interaction with the viral 
haemagglutinin glycoprotein (Weis et al., 1988). Influenza has been shown to enter 
host cells via multiple different pathways which include clathrin-dependent and 
clathrin- and caveolin independent endocytic mechanisms (Nunes-Correia et al., 
2004, Rust et al., 2004). Clathrin-mediated endocytosis is initiated as clathrin and 
associated proteins accumulate on the surface of cellular membranes. The 
accumulation of these proteins at the surface causes invaginations or pits to form 
which pinch off into the cell as vesicles through the action of the GTPase dynamin. 
Vesicles progress to early endosomes and become increasingly acidic as they 
progress into late endosomes. Caveolin-mediated endocytosis is slower than 
clathrin-mediated endocytosis and the resulting vesicles do not become acidic. The 
caveolar pathway is a dynamin and cholesterol dependent pathway (Kalia and 
Jameel, 2011). Caveolar are micro-invaginations of the plasma membrane which 
are involved in signal transduction (Anderson, 1998). Internalisation of virus by 
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endocytosis into caveosomes is initiated by cell stimulation (Ceresa and Schmid, 
2000, Sieczkarski and Whittaker, 2002). 
 
Once the virus is internalised into an endosome haemagglutinin, a glycoprotein 
trimer, experiences an irreversible conformational change at low pH which allows for 
the insertion of a coiled peptide (Yu et al., 1994) of the haemagglutinin trimer into 
the membrane (Thorley et al., 2010). This action brings the viral envelope and 
endosomal membranes in close proximity which assists in membrane fusion (Doms 
et al., 1985, Chambers et al., 1990, Yu et al., 1994). Viral ribonucleoproteins escape 
into the cytosol and are imported into the nucleus, where replication occurs 
(Lakadamyali et al., 2004). Fusion of the viral membrane with the host membrane is 
therefore the successful route of enveloped virus entry (Figure 1.5). Non-enveloped 
viruses, however, cannot use this method as they do not possess a membrane. 
Penetration of the host membranes is therefore used instead.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Several enveloped viruses use endocytosis and fusion with the endosomal 
membrane to gain entry into host cells. The virus interacts with the receptor(s), co-
receptor(s) and/or attachment factors (A) which initiates endocytosis (B). The virus uses a 
pH dependent or independent mechanism to allow for fusion with the endosomal membrane 
(C) before releasing viral nucleic acids into the cytoplasm (D), adapted from Karlsson 
Hedestam et al. (2008). 
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1.3.2 Non-enveloped Virus Entry 
Non-enveloped viruses use endocytic pathways such as clathrin-coated pits and 
caveolar pathways to gain access into host cells. These viruses then penetrate 
membranes of endosomes or caveosomes to release into the host cytoplasm. 
Conformational change of the virus particles, due to receptor binding and/or low pH 
conditions, aid in penetration (Hogle, 2002, Rossmann et al., 2002). Four non-
enveloped viruses which have been studied extensively and their mechanism of 
entry understood fairly well include the Poliovirus, Simian virus 40 (SV40), 
Adenovirus and Bluetongue virus. These viruses use different mechanisms of entry 
and penetration. 
 
Poliovirus of the Picornaviridae family (Table 1.1) causes human poliomyelitis. Cell 
entry of poliovirus is independent of clathrin and caveolar pathways (Brandenburg et 
al., 2007), but uses a tyrosine kinase- and actin-dependent, endocytic mechanism 
instead. Infection is initiated when the virus binds the poliovirus receptor (PVR, or 
CD155) which results in the virus capsid undergoing a conformational 
rearrangement (Mendelsohn et al., 1989). The rearrangement causes the exposure 
of the N-terminus of capsid protein, VP1 and myristoylated auto-cleavage peptide 
VP4, which are capable of inserting into liposomes (Fricks and Hogle, 1990, Belnap 
et al., 2000). After insertion these sequences form a transmembrane pore which 
allows genomic RNA to pass through into the host cytoplasm (Hogle, 2002). 
 
SV40 is a Polyomavirus which uses the caveolar pathway (Pelkmans and Helenius, 
2002) (Figure 1.6). Endocytosis via the caveolar is followed by a series of complex 
signalling which results in the release of virus from the caveosome into the 
cytoplasm of the host cell. The Adenovirus of the Adenoviridae family (Table 1.1) is 
a DNA virus which enters the host cell membrane through endocytosis via clathrin-
coated pits (Blumenthal et al., 1986) (Figure 1.7). Low pH conditions in the late 
endosome cause partial disassembly and a conformational change in the structure 
of the virus which renders the adenovirus particles hydrophobic and therefore able 
to permeabilise endosomes and release viral particles (Blumenthal et al., 1986). 
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Figure 1.6 Several viruses like SV40 use the caveolar pathway to gain entry into host 
cells. Caveolae, which are part of the actin cytoskeleton, trap viruses bound to cell surface 
receptors (1) triggering a signal transduction cascade which leads to tyrosine 
phosphorylation and depolymerisation of the actin cytoskeleton (2). Monomers of actin form 
an actin patch (3) while Dynamin simultaneously moves to the caveolae causing a 
spontaneous actin polymerisation on the actin patch (4). Caveosomes containing virus are 
therefore released from the membrane and move into the host cytoplasm (5), allowing the 
actin cytoskeleton to return back to normal (6), (Pelkmans and Helenius, 2002). 
 
 
Bluetongue virus of the Reoviridae family (Table 1.1) also utilises clathrin-dependent 
endocytosis for entry (Figure 1.7) and has two capsid proteins, VP2 and VP5. VP5 is 
structurally similar to class 1 fusion proteins of enveloped viruses and is capable of 
undergoing pH-dependent conformational changes which allow it to act as a 
membrane permeabilisation protein that mediates release of viral particles from 
endosomal compartments into the cytoplasm (Forzan et al., 2004). Table 1.1 shows 
the receptors used by enveloped and non-enveloped animal viruses. 
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Figure 1.7 Many viruses use clathrin-dependent endocytosis through clathrin-coated 
pits to gain access into host cells. Clathrin coated pits pinch off into the host cytoplasm 
through the GTPase dynamin where vesicles progress into early endosomes increasing in 
acidity. Decrease in pH causes a conformational change of virus which assists fusion or 
penetration of the endosomal membrane allowing for the release of viral nucleic acids, (Kalia 
and Jameel, 2011). 
 
 
1.3.3 IBDV Entry 
The mechanism of IBDV entry is still unknown, however, studies have shown that 
the entry may involve pep46, a structural peptide released from the processing of 
pVP2 (Galloux et al., 2007). Galloux et al. (2007) reported that pep46 is capable of 
deforming synthetic membranes and inducing pores which can be visualised by 
electron microscopy. The study also showed that the entry mechanism is dependent 
on calcium concentration. The lowering of the calcium concentration was found to 
promote the release of pep46 which induced the formation of pores in the 
endosomal membrane. The theory therefore is that IBDV gains entry into host cells 
by two steps which are endocytosis followed by endosome permeabilisation. The 
low calcium concentration levels within the endosomes causes pep46 to induce pore 
formation and thus releasing the virus into the host cytoplasm. 
 
IBDV infects mainly the B-cells of the bursa of Fabricius, but has also been shown to 
infect CEF cells (Yamaguchi et al., 1996a, Rekha et al., 2014), LSCC-BK3 cells, a 
bursal-derived lymphoblastoid cell line (Ogawa et al., 1998), Vero cells (Kwon and 
Kim, 2004), macrophages (Khatri and Sharma, 2007), DF-1 cells, an immortalised 
cell line derived from primary CEF cells (Lin et al., 2007, Rekha et al., 2014) and 
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DT-40 cells, an avian leukosis virus-induced chicken B cell line (Delgui et al., 
2009a). Attenuation of vvIBDV through serial blind passages in tissue culture results 
in the change of three residues at positions 253, 279 and 284 in VP2 and these 
residues are believed to engage in receptor binding (Lim et al., 1999, van Loon et 
al., 2002). This finding suggests that attenuated and very virulent strains use 
different receptors, however, it was later shown that D78, an attenuated viral strain, 
blocked the binding of both strains to Vero cells and therefore indicating that both 
strains utilise the same receptor(s) (Yip et al., 2007). 
 
Initial studies indicated that IBDV targets cells that carry surface IgM (sIgM) (Hirai 
and Calnek, 1979). However, it was later shown that IBDV could bind sIgM negative 
cells (Ogawa et al., 1998). Addition of an antibody against sIgM did not inhibit the 
binding of IBDV to sIgM which further showed that sIgM is not the IBDV receptor 
(Ogawa et al., 1998). Ogawa et al. (1998) treated chicken B-cells with proteases 
and N-glycosylation inhibitors which reduced IBDV infection suggesting the 
receptor(s) to contain an N-glycosylated polypeptide(s). Saturation and competitive 
studies conducted by Nieper and Muller (1996) using CEF cells and chicken B-cells 
revealed that the two IBDV serotypes have both common and serotype specific 
receptors (Nieper and Muller, 1996). The study showed both serotypes specifically 
bound to proteins with molecular masses of 40 kDa and 46 kDa on CEF cells and 
lymphoid cells in a virus overlay protein binding assay (VOPBA) suggesting 
common receptor sites of IBDV. A VOPBA using vvIBDV showed virus particles 
binding to proteins of 70, 80 and 110 kDa which were expressed in LSCC-BK3 cells 
(Setiyono et al., 2001) and later it was shown that chicken heat shock protein 90 
(cHsp90) formed part of the putative cellular receptor which is essential for IBDV 
entry into DF-1 cells (Lin et al., 2007). Additionally, a study conducted by Delgui et 
al. (2009b) determined that IBDV may also use the α4β1 integrin as a specific 
binding receptor in avian cells. The research to date on cellular receptor(s) for IBDV 
has only revealed the size and nature of the receptor and the discovery of cHcp90 
was the first study to actually identify a specific molecule. 
 
Virus attachment to host cells is the first step in the virus life cycle and therefore a 
critical step. Research continues on in attempts to identify the IBDV receptor(s) on 
host cells which could lead to the development of anti-viral agents which prevent 
infection of IBDV like the drug compound, PRO 542, successfully developed to 
control HIV entry into host cells (Jacobson et al., 2000, Shearer et al., 2000).
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Table 1.1 Virus pathogenesis and tropism is dependent on the presence of specific receptor(s) or molecules 
FAMILY VIRUS 
ENVELOPED 
/NON-
ENVELOPED 
RECEPTOR/ 
CO-RECEPTOR 
NUCLEIC 
ACID 
TROPISM DISEASE 
Orthomyxoviridae Influenza Env Sialic acid dsRNA Respiratory tract Influenza 
Retroviridae HIV Env CD4, CCR5, CXCR4 dsRNA 
Macrophages, T-cells, 
dendritic cells, microglia 
brain cells 
Lymphadenopathy, 
AIDS, encephalopathy 
Flaviviridae 
Hepatitis C Env CD81, SR-BI and CLDN1 ssRNA Hepatocytes 
Cirrhosis and 
hepatocellular 
carcinomas 
Dengue Env 
Heparan sulfate, HAR and 
FcR 
ssRNA 
Monocytes/ 
macrophages 
Febrile illness, 
haemorrhagic fever or 
shock syndrome 
Paramyxoviridae Measles Env 
CD46, second unknown 
receptor 
 
Respiratory tract 
mononuclear cells 
endothelial cells 
Acute measles, 
encephalitis and SSPE 
(Spillner et al., 2012) ssRNA 
Rhabdoviridae Rabies Env Acetylcholine ssRNA Neuronal tissue Rabies: encephalitis 
Picornaviridae 
Polio Non-Env 
Polio virus receptor (PVR) 
or CD155 
ssRNA Epithelial cells neurons 
Enteric infection 
poliomyelitis 
Echovirus 1 Non-Env 
Complement inhibitor 
CD55/DAF 
ssRNA 
Gastrointestinal tract, 
other tissues 
Febrile illness meningitis 
Adenoviridae Adenovirus Non-Env 
CAR (Ig superfamily)  
αvβ3 and αvβ5 integrins 
dsDNA 
Epithelial cells, lymphoid 
cells 
Respiratory infection, 
lymphoid tissues 
Reoviridae Bluetongue Non-Env 
β-adrenergic hormone 
receptor 
dsRNA 
Epithelial cells and other 
tissues 
Reproductive/neonatal 
disease 
Polyomaviridae SV40 Non-Env MHC Class 1 dsDNA Mesothelial cells 
Tumour and kidney 
disease 
Birnaviridae IBDV Non-Env Unknown dsRNA 
Macrophages, 
lymphocytes and other 
tissues 
Infectious bursal 
disease (IBD) 
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1.4 OBJECTIVES OF THIS STUDY 
Infectious bursal disease is an economically important disease of poultry even 
though there are widely used vaccination programmes in place. Not only does it 
cause mortality in young chickens, but it also increases the susceptibility of other 
opportunistic pathogens and a poor vaccination response through 
immunosuppression (van den Berg et al., 2000, Yuan et al., 2012). Additionally, 
early vaccination is obstructed by maternally derived antibodies and therefore, new 
strategies and drugs targeted at different stages of the life cycle are required. The 
initial and one of the most important steps in the life cycle is receptor binding, which 
initiates virus entry into host cells. Therefore, identifying the receptor(s) could lead to 
development of antiviral agents which targets receptor binding. Since VP2 is the 
receptor binding protein of IBDV, the aim of this study was to identify possible IBDV 
receptor(s) on the plasma membrane of the bursa of Fabricius using recombinant 
VP2.  
 
In the present study, a virus overlay protein binding assay (VOPBA) and affinity 
chromatography was used to determine IBDV receptor(s) with the help of VP2.  
Therefore the first objective was the production of sufficient VP2 for experimental 
use. VP2 was therefore heterologously expressed in E. coli and Pichia pastoris. The 
VP2 coding sequence which was previously cloned into a T-vector and E. coli 
expression vectors, was subcloned into P. pastoris yeast expression vector pPIC9. 
The recombinantly expressed VP2 protein was purified using three phase 
partitioning (TPP) and chromatographic techniques. In preparation for the VOPBA 
and affinity chromatography, the purified VP2 was used to raise polyclonal anti-VP2 
antibodies in chickens and used to prepare a VP2-coupled affinity matrix. In 
addition, VP2 peptides were designed from the VP2 amino acid sequence and used 
to raise polyclonal anti-VP2 peptide antibodies to compare the specificity of the 
different antibodies. These results are described in Chapter 2. 
 
The second objective was to identify the VP2-binding proteins and potential IBDV 
receptor(s). To this end, plasma membrane proteins were isolated from non-infected 
bursa and used in a modified VOPBA with recombinant VP2 and chicken anti-VP2 
antibodies or chicken anti-VP2 peptide antibodies to identify VP2-binding proteins. 
In addition, all VP2-binding proteins were purified from the plasma membrane 
preparation on the VP2-coupled affinity matrix and further identified using tandem 
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mass spectrometry. The results of this part of the study are presented in Chapter 3 
while the main findings are discussed in Chapter 4. 
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CHAPTER 2 
RECOMBINANT EXPRESSION AND PURIFICATION OF THE 
IBDV CAPSID PROTEIN, VP2 AND ANTIBODY PRODUCTION 
 
2.1 INTRODUCTION 
A novel strategy to control IBDV infection would be blocking viral entry which is the 
first step in the virus life cycle (Smith and Helenius, 2004). Virus receptors have 
been successfully used in the design of antiviral drugs which target virus entry 
(Altmeyer, 2004) much like anti-HIV T20 (Fuzeon, enfuvirtide) which was the first 
virus entry inhibitor approved for use as an HIV-1 fusion inhibitor (Walmsley et al., 
2003, Hardy and Skolnik, 2004). Several studies using various methods and 
approaches have been conducted on identifying the IBDV receptor(s). Saturation 
and competitive studies in chicken embryo fibroblast (CEF) cells and chicken B-cells 
identified two proteins of 40 and 46 kDa to which IBDV specifically bound (Nieper 
and Muller, 1996). Saturation experiments involved binding excess radiolabelled 
IBDV with CEF cells and measuring the affinity of IBDV for receptors on CEF cells. 
In competition experiments CEF cells were bound to a fixed concentration of 
radiolabelled IBDV and then incubated with unlabelled IBDV. The virus ability to 
competitively bind CEF cells was then determined. Later, Ogawa et al. (1998) 
demonstrated the ability of IBDV to infect LSCC-BK3 cells (chicken lymphoblastoid 
cell line) and observed that treatment of the cells with proteases and N-glycosylation 
inhibitors prevented infection, suggesting that the receptor(s) contain(s) an N-
glycosylated protein necessary for infection. A virus overlay protein binding assay 
(VOPBA) showed that IBDV specifically bound to proteins with molecular masses of 
70, 80 and 110 kDa on LSCC-BK3 cells (Setiyono et al., 2001). Whole virus was 
used in these studies to determine which proteins IBDV bound to on IBDV 
susceptible cells. 
 
Previous studies have only identified the size or nature of the host cellular 
receptor(s) and it was only later that chicken heat shock protein 90 (cHsp90) was 
identified as a possible cellular receptor or forming part of the cellular receptor (Lin 
et al., 2007). This study made use of DF-1 cells from a spontaneously immortalised 
cell line, in turn derived from primary CEF cells. Recombinantly expressed IBDV 
subviral particles (SVPs), instead of whole virus, and monoclonal anti-SVP 
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antibodies were used in a VOPBA and in affinity chromatography to identify possible 
receptor(s). The SVPs are formed by VP2 assembly and show the same 
immunogenicity as IBDV particles (Coulibaly et al., 2005, Lin et al., 2007). Even 
though several studies have been conducted to identify the IBDV receptor(s) on 
bursal cells, little is known about the nature of the receptor(s) or the possible 
existence of co-receptors. The proteins of different cell lines which bind to IBDV 
have been reviewed by Zhu et al. (2008) and are summarised in Table 2.1. 
 
Table 2.1 Summary of IBDV binding proteins of different cell lines to date 
CELL LINE 
PROTEIN IDENTITY/ 
MOLECULAR MASS (kDa) 
STUDY CONDUCTED BY 
CEF 
B-lymphocytes 
40 and 46 Nieper and Muller (1996) 
LSCC-BK3 70, 80 and 110 Setiyono et al. (2001) 
DF-1 cHsp90 Lin et al. (2007) 
 
 
Since SVPs were used to identify cHsp90 as forming part of the cellular receptor, 
VP2 is a good substitute for the identification of IBDV receptor(s) on bursal cell 
membranes. Therefore the aim of this part of the study was to recombinantly 
express VP2 and produce chicken anti-VP2 antibodies for use in a VOPBA and by 
VP2- affinity chromatography as will be described in Chapter 3. To this end the VP2 
coding sequence was sub-cloned and heterologously expressed in bacterial and 
eukaryotic expression systems and antibodies produced against VP2 and a VP2 
peptide. The VP2 coding sequence amplified from IBDV segment A cDNA was 
previously cloned into a T-vector and sub-cloned into pGEX-4T-1 and pET-32a 
expression vectors. In the present study bacterial expression of VP2 was achieved 
using the pET-32a construct by auto-induced expression in E. coli and the 
recombinant VP2 was affinity purified via the His-tag and used to raise polyclonal 
antibodies in chickens. The VP2 coding sequence was additionally sub-cloned into 
the pPIC9 yeast expression vector and expression carried out in P. pastoris to 
obtain a higher yield of purified VP2. VP2 expressed in P. pastoris was purified 
using three phase partitioning (TPP) and molecular exclusion chromatography 
(MEC) and was coupled to an affinity matrix for the purification of chicken anti-VP2 
antibodies. 
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2.2 MATERIALS 
General molecular biology: The following reagents were obtained from Fermentas 
(Vilnius, Lithuania): NotIa, EcoRI, SacI O’GeneRuler™ 1 kb DNA ladder, 
MassRuler™ DNA ladder mix, Taq DNA polymerase, T4 DNA ligase, 10 mM dNTP 
mix, shrimp alkaline phosphatase, TransformAid™ bacterial transformation kit, 
GeneJET™ plasmid miniprep kit and PageRuler™ prestained protein ladder. The 
peqGOLD gel extraction kit was purchased from PEQLAB Biotechnologie (Erlangen, 
Germany) and the DNA clean and concentrator kit™ from Zymo Research (Orange, 
USA). Tetracycline, ampicillin and isopropyl thioglucopyranoside (IPTG) were 
purchased from Sigma-Aldrich-Fluka (Steinheim, Germany) and urea from Merck 
Biosciences (Damstadt, Germany). Expression vector, pPIC9, was provided as a 
glycerol stock by Dr P. Vukea [University of KwaZulu-Natal, (UKZN)]. In previous 
studies in the laboratory, the mature VP2 coding region was cloned into pET-32a 
and pGEX-4T-1 expression vectors and transformed into E. coli BL21(DE3) cells 
and in E. coli BL21 cells respectively. Both were available as glycerol stocks. 
 
General biochemistry: BioTrace™ NT nitrocellulose membrane was purchased 
from PALL Corporation (New York, USA) and BCA™ protein assay kit from Pierce 
(Rockford, USA). Poly-Prep® chromatography columns and Oriole™ fluorescent gel 
stain were purchased from Bio-Rad (Hercules, USA) and Sephacryl™ S300 HR, 
SP-Sephadex C-25 and rabbit anti-IgY-horse radish peroxidase (HRPO) from 
Sigma-Aldrich-Fluka (Steinheim, Germany). Filter paper was obtained from 
Whatman (Middlesex, UK) and Amicon Centricon® centrifugal concentrators were 
purchased from Millipore (Billerica, USA). Nunc Maxi Sorp™ 96-well microtiter 
plates were from Nunc products (Roskilde, Denmark). Ni-NTA His-bind resin and 
mouse anti-His tag monoclonal antibody were purchased from Novagen (Damstadt, 
Germany). Horse anti-mouse IgG-HRPO conjugate was purchased from Cell 
Signaling Technology® (Boston, USA), polyethylene glycol (PEG) 6000 from Merck 
Biosciences (Damstadt, Germany) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) (ABTS), dithiothreitol (DTT) and bovine serum albumin (BSA)  were 
purchased from Roche (Mannheim, Germany). Chickens used for immunisations 
were obtained from UKZN Ukulinga research and training farm and approval for 
antibody production obtained from the UKZN Animal Research Ethics Committee 
                                                          
a
 Nomenclature according to Roberts et al. (2003) where gene names are in italics and 
restriction enzymes are not. 
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(reference number 36/11/Animal). All other general reagents and chemicals were 
obtained from Sigma-Aldrich-Fluka (Steinheim, Germany) and Merck Biosciences 
(Damstadt, Germany). 
 
Antibody preparation: The peptides designed for antibody production were 
synthesised by GL Biochem (Shanghai, China). Freund's complete and incomplete 
adjuvants, Sephadex® G-10 and Sephadex® G-25 resins, maleimidobenzoyl-A/-
hydroxysuccinimide ester (MBS), rabbit albumin and Ellman's reagent were 
purchased from Sigma-Aldrich-Fluka (Steinheim, Germany). Aminolink® and 
Sulfolink® coupling resins were purchased from Pierce Perbio Science 
(Erembodegem, Belgium). 
 
 
2.3 METHODS 
2.3.1 Expression of VP2 in E. coli 
2.3.1.1 VP2 expression using pGEX-4T-1 
The VP2 coding sequence was previously cloned into the pGEX-4T-1 vector (Figure 
2.1) between the EcoRI and NotI sites. Glycerol stocks of E. coli BL21 cells containing 
recombinant pGEX-4T-1 were three-way streaked on 2xYT agar plates [1.6% (w/v) 
tryptone, 1% (w/v) yeast extract, 1.5% (w/v) agar, 86 mM NaCl]  containing 50 
µg/mL ampicillin and grown inverted overnight at 37°C.  A single colony was thereafter 
inoculated in 2xYT broth containing 50 µg/mL ampicillin (2xYT-Amp) (10 mL) and the 
cultures were grown overnight with shaking at 37°C. The overnight culture was diluted to 
100 mL using fresh 2xYT-Amp and grown at 37°C with shaking until an OD600 between 
0.4 and 0.6 was reached. Cultures were induced for expression by the addition of IPTG to 
a final concentration of 1 mM and incubation continued at 37°C with shaking for another 
4 h. Ampicillin (50 µg/mL) was added to the culture every hour during expression to 
maintain selective pressure for transformed E. coli. After 4 h the cells were pelleted by 
centrifugation (5 000 x g, 5 min, RT) and resuspended in lysis buffer [PBS (100 mM 
Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4), 0.1% (v/v) Triton X-
100, 1 mg/mL lysozyme] for 30 min at 37°C and subsequently frozen at -20°C.  
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Figure 2.1 Structure of pGEX-4T-1 expression vector. The vector is 4 950 bp in size and 
contains an ampicillin resistance marker (Ampi R), lac promoter (Lac I), tac promoter (P tac), 
a glutathione S-transferase gene and a multiple cloning site (MCS) in which the VP2 coding 
sequence was cloned between the EcoRI and NotI restriction sites. The MCS also has a 
thrombin cleavage site which allows for the GST-tag to be cleaved from the recombinant 
protein after expression. 
 
 
2.3.1.2 VP2 expression using pET-32a 
The VP2 coding sequence was previously cloned into the pET-32a vector (Figure 2.2) 
between the EcoRI and NotI sites. Glycerol stocks of E. coli BL21(DE3) cells 
containing recombinant pET-32a were three-way streaked on 2xYT agar plates 
containing 50 µg/mL ampicillin and grown inverted overnight at 37°C. Expression was 
carried out by either auto-induction or IPTG induction. Auto-induced expression was 
carried out at 30°C or 37°C overnight or at 16°C or 25°C over 24 h. A single 
recombinant colony was inoculated in Terrific broth [1.2% ((w/v)) tryptone, 2.4% 
(w/v) yeast extract, 0.4% (v/v) glycerol, 0.17 M KH2PO4, 0.72 M K2HPO4] containing 
50 µg/mL ampicillin with shaking. Cultures were centrifuged (5 000 x g, 5 min, RT), 
the cell pellet resuspended in 1/10 culture volume of lysis buffer and frozen at -20°C. 
 
Expression induced by IPTG was carried out by inoculating 10 mL of 2xYT-Amp with 
a single recombinant colony and allowing the cultures to grow overnight with 
shaking at 37°C. The overnight culture was diluted to 100 mL with fresh 2xYT-Amp broth 
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and grown at 37°C with shaking until an OD600 between 0.4 and 0.6 was reached. 
Expression was induced by the addition of IPTG to a final concentration of 1 mM and the 
cultures were further incubated for 4 h. Non-induced cultures were also incubated for 4 h 
as negative controls. The cells were harvested by centrifugation (5 000 x g, 10 min, 
RT) and the cell pellet was resuspended in 1/10 culture volume of lysis buffer at 37°C 
for 30 min and frozen at -20°C. All lysates were thawed and disrupted by sonication 
before analysis by reducing SDS-PAGE and stained with Coomassie blue R-250 
(Section 2.3.5.2) followed by western blotting (Section 2.3.5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Structure of the pET-32a expression vector and sequence of the pET-32a 
MCS. (A) Schematic map of pET-32a vector. (B) Nucleotide sequence of the MCS of 
pET 32a. The vector contains Trx-Tag, His-Tag and S-tag coding sequences, a MCS in 
which the VP2 coding sequence was cloned between the NotI and  EcoRI restriction sites, 
an f1 origin of replication, ampicillin resistance gene (Ap), lacI promoter (lacI) and a T7 
promoter and transcription start codon. 
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2.3.1.3 Solubilisation of inclusion bodies 
Recombinant VP2 expressed in E. coli BL21(DE3) cells was analysed for solubility. 
The lysates containing expressed proteins were separated into soluble and insoluble 
protein fractions through high speed centrifugation (14 000 x g, 30 min, 4°C). The 
pellet (inclusion bodies) and supernatant (soluble fraction) were analysed by SDS-
PAGE with Coomassie blue R-250 staining (Section 2.3.5.2). Inclusion bodies were 
solubilised according to Sijwali et al. (2001) with a few modifications. Inclusion 
bodies containing VP2 were washed three times in wash buffer (2 M urea, 0.02 M 
Tris-HCl, 1% (v/v) Triton X-100, pH 8.0) with centrifugation between washes (14 000 
x g, 30 min, 4°C). The final pellet was resuspended in solubilisation buffer (8 M urea, 
0.02 M Tris-HCl, 0.5 M NaCl, pH 8.0) and incubated at 4°C overnight. Undissolved 
debris was removed by centrifugation (14 000 x g, 30 min, 4°C) before the 
solubilised proteins were analysed by SDS-PAGE stained with Coomassie blue 
R-250 (Section 2.3.5.2). 
 
 
2.3.2 Purification of recombinant VP2 from E. coli expression systems 
2.3.2.1 Purification of VP2 under denaturing conditions using a nickel column 
The His-tagged VP2 expressed as insoluble proteins using the pET-32a system. 
Therefore solubilised inclusion bodies were purified under denaturing conditions on 
a nickel column. The Ni-NTA His-Bind resin (Novagen, Germany) (2 mL) was 
packed into a 10 mL Poly-Prep® chromatography column (Bio-Rad, USA) and 
prepared according to the manufacturer’s instructions. The column was equilibrated 
with 10 column volumes of equilibration buffer (8 M urea, 0.02 M Tris, 0.5 M NaCl, 
0.02 M imidazole, 0.001 M -mercaptoethanol, pH 8.0) under gravitational flow-rate. 
The solubilised proteins were incubated overnight at 4°C with the resin by end-over-
end rotation, after which the unbound proteins were collected from the column. The 
column was washed with 10 column volumes of wash buffer (8 M urea, 0.02 M Tris, 
0.5 M NaCl, pH 8.0) and bound proteins were eluted from the column with elution 
buffer (8 M urea, 0.02 M Tris, 0.25 M imidazole, pH 8.0) in 0.5 mL fractions. Eluted 
fractions were analysed by SDS-PAGE stained with Coomassie blue R-250 (Section 
2.3.5.2) and analysed by western blotting (Section 2.3.5.3). All eluted fractions 
containing VP2 were pooled and all wash fractions containing VP2 were pooled 
separately and further purified using ion exchange chromatography (IEC). 
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2.3.2.2 Purification of VP2 from wash fractions using IEC 
Wash fractions containing VP2 from the affinity purification of recombinantly 
expressed His-tagged proteins were pooled and further purified using cation-
exchange chromatography on a SP-Sephadex C-25 cation-exchange column 
(Himmelhoch, 1971). The pooled wash fractions were prepared for IEC by two 
dialysis steps in IEC buffer (0.1 M Na-citrate, pH 5.9) with stirring at 4°C for 48 h and 
thereafter concentrated against PEG Mr 20 000. The column (25 x 150 mm, 
30 mL/h, RT) was packed and prepared according to the manufacturer’s instructions 
and equilibrated with 10 column volumes of IEC buffer. The concentrated sample 
was loaded onto the column followed by washing with IEC buffer. The A280 readings 
of the wash fractions (1 mL) were monitored to determine when all unbound proteins 
were completely eluted. Once the A280 reached baseline, bound proteins were eluted 
using a step-wise gradient of NaCl (50, 100 and 500 mM NaCl in IEC buffer). 
One mL fractions were collected and monitored for protein by measuring A280. 
Elution peaks were analysed by SDS-PAGE followed by staining with silver nitrate 
(Section 2.3.5.2). 
 
 
2.3.2.3 On-column refolding and affinity purification of VP2 
Solubilised His-tagged VP2 was subjected to on-column refolding on a nickel 
column. The refolding of solubilised VP2 was performed by using a linear urea 
gradient from 8.0 M urea to 0 M urea. The column was washed starting with the 
washing buffer (8 M urea, 0.02 M Tris-HCl, 0.5 M NaCl, pH 8.0) and finishing with 
refolding buffer (0.02  Tris-HCl, 0.5 M NaCl, pH 8.0) with a total gradient volume of 
40 mL at a flow rate of 0.5 mL/min. The refolded VP2 was eluted using elution buffer 
(0.02 M Tris-HCl, 0.5 M NaCl, 0.25 M imidazole, pH 8.0) and collected in 0.5 mL 
fractions before analysis by SDS-PAGE, stained with silver nitrate (Section 2.3.5.2).  
 
 
2.3.2.4 Electro-elution of VP2 and high molecular mass proteins 
Electro-elution was used to purify high molecular mass proteins observed 
expressing in the E. coli system, for further identification. Electro-elution was carried 
out according to Acil et al. (1997) with minor modifications. Lysates containing 
expressed proteins were separated on 10% reducing SDS-PAGE (Section 2.3.5.2) 
and protein bands were visualised by staining with 0.3 M CuCl2 for 10 min. Protein 
bands of interest were excised and destained by repeated washes (3 x 10 min) in 
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destain buffer (0.25 M Tris-HCl, 0.25 M EDTA, pH 8.0) with gentle shaking. Gel 
slices were equilibrated in electrophoresis buffer (20 mM Tris-HCl, 1.7 mM SDS, pH 
8.5) for 5 min, cut into small pieces and placed into an electro-elution chamber and 
eluted at 80 V for 16 h at RT using the Electro-Eluter Concentrator (CBS Scientific, 
California, USA). The eluted proteins were analysed by SDS-PAGE, stained with 
silver nitrate (Section 2.3.5.2). 
 
 
2.3.3 Expression of VP2 in P. pastoris 
2.3.3.1 Sub-cloning of the VP2 coding region into pPIC9 yeast expression vector 
The E. coli JM109 glycerol stocks containing recombinant pGEX-4T-1-VP2 and 
pPIC9 vector (Figure 2.3) were separately three-way streaked on 2xYT agar plates 
containing 50 µg/mL ampicillin and grown inverted overnight at 37°C.  A single 
colony was used to inoculate 10 mL 2xYT-Amp and grown overnight at 37°C with 
shaking. The recombinant pGEX-4T-1-VP2 and non-recombinant pPIC9 plasmids 
were isolated from the overnight cultures using the GeneJET™ plasmid miniprep kit 
(Fermentas, Lithuania) according to the manufacturer’s instructions with minor 
modifications. Instead of eluting with 50 µL, the elution step was done twice with 
25 µL. Purified plasmid DNA was analysed on a 1% ((w/v)) agarose gel (Section 
2.3.5.1) to determine purity.  
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Structure of pPIC9 yeast expression vector. The vector contains a ColE1 
origin of replication (pBR322), 3’ AOX fragment (3’ AOX1), a HIS4 gene, which is used for 
selection by complementation in the his4 yeast strain, c-myc epitope (TT), MCS in which the 
VP2 coding sequence was cloned between the EcoRI and NotI restriction sites, α-factor 
secretion signal (S), 5’ AOX fragment (5’ AOX1) and an ampicillin resistance gene. The 
vector size is 8.0 kb. 
 
 
The recombinant pGEX-4T-1-VP2 and non-recombinant pPIC9 plasmid DNA were 
subjected to a double restriction digest with EcoRI and Notl to release the VP2 insert 
cDNA and prepare the pPIC9 vector for ligation, respectively. The double restriction 
was carried out in a 30 µL reaction containing 10 x buffer O (3 µL), plasmid DNA 
(25 µL), EcoRI (1 µL or 10 U) and Notl (1 µL or 10 U). The digestion reaction was 
incubated overnight at RT and analysed on a 1% (w/v) agarose gel (Section 2.3.5.1) 
to assess digestion. The enzymes in the reaction tube for the digestion of pPIC9 
vector were deactivated by incubation at 65°C for 15 min prior to dephosphorylation. 
The dephosphorylation reaction, containing 10 x reaction buffer (3 µL), digestion 
reaction mix (26 µL) and shrimp alkaline phosphatase (1 µL) was incubated for 1 h 
at 37°C. The shrimp alkaline phosphatase was deactivated by incubation at 65°C for 
15 min and the dephosphorylated vector was purified using the DNA clean & 
concentrator™ kit (Zymo Research, USA) according to the manufacturer’s 
instructions.  
 
The remaining reaction mix of the digested recombinant pGEX-4T-1 plasmid DNA 
was electrophoresed on a 1% (w/v) agarose gel and the band corresponding to the 
VP2 insert cDNA was extracted from the gel using the gel extraction kit (PEQLAB 
Biotechnologie, Germany) according to the manufacturer’s instructions. Purified VP2 
cDNA was ligated into pPIC9 vector using T4 DNA ligase (Fermentas, Lithuania) 
according to the manufacturers’ instructions. Negative controls omitting either insert 
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DNA or T4 DNA ligase were also included. The ligation mixture was incubated 
overnight at 4°C and the ligation mixtures were used to transform E. coli JM109 cells 
using the TransformAid™ bacterial transformation kit (Fermentas, Lithuania) 
according to the manufacturer’s instructions. The transformed cells were grown 
overnight at 37°C on 2xYT agar plates containing 50 µg/mL ampicillin. Colonies were 
screened for recombinant plasmids by colony PCR using AOX vector primers (forward 
5’-GACTGGTTCCAATTGACAAG-3’ and reverse 3’-GCAAATGGCATTCTGACATCC-5’) in 
a PCR reaction mix containing 1 x PCR buffer, 2.5 mM MgCl2,  0.25 µM AOX forward 
primer, 0.25 µM AOX reverse primer, 0.5 mM dNTP mix and 0.25 U Taq polymerase. 
Amplification was carried out as follows: 94°C (5 min) for initial denaturation, then 30 
cycles of 94°C (30 s), 55°C (30 s) and 72°C (1 min) for denaturation, annealing and 
extension followed by final extention at 72°C (7 min). 
 
A single recombinant colony was used to inoculate 2xYT broth containing 50 µg/mL 
ampicillin and grown overnight with shaking at 37°C. The pPIC9-VP2 plasmid DNA 
was purified using the GeneJET™ plasmid miniprep kit (Fermentas, Lithuania) and 
analysed on a 1% (w/v) agarose gel (Section 2.3.5.1) before linearisation of the 
recombinant plasmid DNA with SacI to allow for integration into the P. pastoris 
genome. Transformation of the pPIC9 recombinants were carried out according to Wu 
and Letchworth (2004). Briefly, P. pastoris GS115 cells were grown in 500 mL yeast 
peptone dextrose medium (YPD) [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) 
dextrose] at 30°C overnight, with shaking until an OD600 of between 1 and 2 was 
reached. The GS115 cells were pelleted by centrifugation (708 x g, 20 min, 4°C) and 
resuspended in 400 mL resuspension buffer (100 mM lithium acetate, 10 mM DTT, 0.6 
M sorbitol, 10 mM Tris-HCl buffer, pH 7.5) and incubated for 30 min at RT. The cells 
were again pelleted (708 x g, 20 min, 4°C) and washed with ice-cold 1 M sorbitol (45 mL) 
three times with centrifugation between washes (708 x g, 20 min, 4°C) before 
resuspending the final pellet in ice-cold 1 M sorbitol (1.5 mL).  
 
The prepared P. pastoris GS115 cells (200 µL) were added to linearised pPIC9-VP2 
(2 µL) and allowed to incubate on ice for 5 min. The mixture was transferred to pre-
chilled 2 mm electroporation cuvettes (BioRad, USA) and electroporated (1.5 kV, 25 µF, 
186 ) using a BioRad Gene Pulser™ electroporator (BioRad, USA). Immediately after 
electroporation, 1 mL ice cold 1 M sorbitol was added to the cells and 200 µL were 
plated onto minimal dextrose (MD) plates [1.34% (w/v) YNB, 0.00004% (w/v) biotin, 2% 
(w/v) dextrose (glucose), 15 g/L bacteriological agar] containing 50 µg/mL ampicillin and 
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grown for four days at 30°C. A colony PCR was performed using AOX vector primers 
to screen for recombinants (Ayra-Pardo et al., 1998). Positive clones were inoculated 
in YPD and grown overnight with shaking at 30°C and stored in sterile 80% (v/v) 
glycerol at -80°C until required for expression. 
 
 
2.3.3.2 Yeast expression of VP2 using pPIC-9 
Glycerol stocks of P. pastoris GS115 cells containing the pPIC9 vector were three-
way streaked on YPD plates containing 50 μg/mL ampicillin. The plates were 
incubated for 48 h at 30°C and single colonies were used to inoculate YPD medium 
(50 mL) and grown for 48 h at 30°C with shaking to saturation. Buffered medium 
glycerol yeast (BMGY) [1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate buffer, pH 6.5, 1.34% (w/v) yeast nitrogen base without amino 
acids] (450 mL) was inoculated with the YPD culture (50 mL) and grown for 48 h at 
30°C with shaking until an OD600 of 3 to 6 was reached. The cells were pelleted by 
centrifugation (708 x g, 10 min, 4°C) and the supernatant discarded. The pellet was 
checked to ensure an off-white homogenous pellet which indicates lack of 
contamination.  
 
The pellet was resuspended in 500 mL buffered minimal medium (BMM) [100 mM 
potassium phosphate buffer, pH 6.5, 1.34% (w/v) yeast nitrogen base without amino 
acids, 0.0004% (w/v) biotin, 5% (v/v) methanol], transferred to sterile baffled flasks 
and covered with three layers of sterile cheesecloth to facilitate aeration during 
expression. Expression was continued for 10 days with shaking at 30°C with the 
daily addition of 0.5% (v/v) methanol for the duration of expression. Cells were 
pelleted by centrifugation (5 000 x g, 10 min, 4°C) and the supernatant retained. The 
pellet was used in another round of expression by resuspending in BMM (500 mL) 
as long as the pellet remained uncontaminated. The supernatant was analysed by 
SDS-PAGE, stained with silver nitrate (Section 2.3.5.2) and stored at -20°C. 
 
 
2.3.3.3 Purification of VP2 by three phase partitioning (TPP) and molecular 
exclusion chromatography (MEC) 
Three phase partitioning (Pike and Dennison, 1989) was the initial method used for 
purification and concentration of VP2 expressed in yeast. Briefly, the supernatants 
(500 mL) were filtered (Whatman No. 4 filter paper) and tertiary-butanol added to a 
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final concentration of 30% (v/v). Ammonium sulfate [40% (w/v)] was added and 
stirred until completely dissolved. This mixture was centrifuged (6000 x g, 10 min, 
4°C) using a spin-out rotor (JS-7.5) in a Beckman Coulter centrifuge to facilitate 
separation into three distinct layers: a lower aqueous layer, an upper tertiary butanol 
layer and a precipitated protein layer at the interface. The precipitated protein layer 
was collected and dissolved in a minimal volume of PBS and dialysed against two 
changes of PBS for 48 h at 4°C to remove t-butanol. The dialysed sample was 
concentrated using PEG 20 000 until the final volume was approximately 5-10 mL 
before analysis by SDS-PAGE, stained with silver nitrate (Section 2.3.5.2). The 
concentrated sample was further purified by MEC. 
 
For MEC a Sephacryl S300 HR column (25 x 840 mm, RT) was calibrated at a flow 
rate of 25 mL/h using 6 mg/mL blue dextran (2000 kDa) and 15 mg/mL each of BSA 
(68 kDa), ovalbumin (45 kDa) and myglobin (16.7 kDa) dissolved in 5 mL MEC 
buffer (0.15 M NaH2PO4, 0.05 M NaCl, pH 7.0) and a calibration curve generated by 
monitoring and recording the A280 readings. The availability constant (Kav) for each 
protein was determined, where the elution volume (Ve) of blue dextran represents 
the void volume (Vo) and Vt is the total column volume. A Fischer’s plot relating Kav 
to log Mr is presented in Figure 2.4. The column was equilibrated with one column 
volume of MEC buffer before applying the TPP protein sample (approximately 5 mL) 
to the column. Eluted fractions were monitored by measuring the A280 and thereafter 
analysed by SDS-PAGE, stained with silver nitrate (Section 2.3.5.2). Fractions 
containing VP2 were pooled and concentrated using Centricon® centrifugal 
concentrators (Millipore, USA) according to the manufacturer’s instructions. 
 
 
 
 
 
 
 
Figure 2.4 Fischer’s plot for the estimation of protein Mr from MEC data. The Sephacryl 
S300 HR column was calibrated by applying a calibration sample in MEC buffer (25 mL/h, 
RT). The availability constant (Kav) was determined for each protein standard. The equation 
of the trend line is y = -0.2178x + 0.664  
with a correlation co-efficient of 0.993. 
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2.3.4 Production of antibodies against VP2 peptides and recombinant VP2 
2.3.4.1 Selection and synthesis of VP2 peptides 
The VP2 amino acid sequence was analysed using the Predict7™ software program 
which analyses protein structure according to the following parameters: 
hydrophilicity, surface probability, flexibility and antigenicity (Cármenes et al., 1989). 
Two peptide sequences which demonstrated high hydrophilicity, surface probability, 
antigenicity and flexibility were selected (Table 2.2). The VP2 crystal structure (Lee 
et al., 2006a) was also used to determine the location of the selected peptides to 
determine if they would be on the surface of the protein. The two peptides were 
modified before synthesis by the addition of an extra cysteine residue to the N- or C- 
terminus, to allow for coupling via M-maleimidobenzoil acid N-hydroxy succinimide 
ester (MBS) to rabbit albumin, the carrier protein. All internal cysteine residues were 
replaced with α-aminobutyric acid to avoid coupling of carrier protein through the 
internal cysteines. Peptides were synthesised by GL Biochem (Shanghai, China) at 
purity greater than 75%.  
 
 
2.3.4.2 Coupling of VP2 peptides to rabbit albumin 
The synthesised peptides were prepared for immunisation by coupling to rabbit 
albumin via MBS that links the SH-group of a cysteine side chain to the -amino 
group of a lysine residue on the carrier protein. The coupling was carried out at a 
peptide:carrier ratio of 40:1 (Briand et al., 1985). The MBS was allowed to react with 
rabbit albumin by mixing 5.26 mg rabbit albumin dissolved in 500 µL PBS with 0.97 
mg MBS dissolved in 200 µL dimethyl formamide (DMF) and incubated with stirring 
for 30 min at RT before applying to a Sephadex® G-25 column (15 x 130 mm, 
10 mL/h). The MBS-activated rabbit albumin was eluted with buffer A [100 mM 
sodium phosphate buffer pH 7.0, 0.02% (w/v) NaN3] in 0.5 mL fractions. Eluted 
fractions were monitored by the A280 readings and all fractions with absorbance 
readings greater than 0.5 were pooled.  
 
To reduce the peptides for coupling, the peptide (4 mg) was dissolved in 50 µL 
dimethyl sulfoxide (DMSO) and made up to 500 µL with peptide buffer [100 mM 
Tris-HCI buffer pH 7.0, 1 mM Na2-EDTA, 0.02% (w/v) NaN3]. The volume was made 
up to 1 mL with 10 mM DTT as reducing agent and incubated for 1 h at 37°C. The 
reduced peptide was separated from the reducing agent and non-reduced peptide 
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on a Sephadex® G-10 column (15 x 110 mm, 10 mL/h) using MEC buffer (0.15 M 
NaH2PO4, 0.05 M NaCl, pH 7.0) in 0.5 mL fractions. Elution fractions were analysed 
for reduced peptides by adding 10 µL Ellman’s reagent [10 mM 5'5 dithiobis (2-nitro-
benzoic acid), 100 mM Tris-Cl buffer pH 8.0, 10 mM Na2-EDTA, 0.1% (w/v) SDS] to 
10 µL of the elution fractions. Fractions containing reduced peptides turned yellow 
and could be distinguished from the second elution peak containing DTT that turned 
bright yellow. The reduced peptide containing fractions were pooled and mixed with 
the pooled MBS-activated rabbit albumin and incubated for 3 h at RT with stirring. 
The solution was equally aliquoted into four microfuge tubes and stored at -20°C 
until immunisation. 
 
 
2.3.4.3 Immunisation of chickens with carrier-conjugated VP2 peptides and 
recombinant VP2 
Hy-Line Brown hens aged between 25 to 40 weeks were used for immunisations. Animal 
ethics clearance was obtained from the UKZN Animal Research Ethics Committee 
(reference number 36/11/Animal). Purified VP2 expressed in E. coli (50 µg) (Section 
2.3.2.3) and rabbit albumin coupled peptide (~200 µg) were separately triturated with 
Freund’s complete adjuvant in a 1:1 (v/v) ratio to form a stable water-in-oil emulsion. 
Two chickens per antigen were immunised intramuscularly in each breast muscle. 
Booster immunisations were prepared by triturating purified VP2 (50 µg) or 200 µg 
rabbit albumin coupled peptide with Freund’s incomplete adjuvant in a 1:1 (v/v) ratio. 
The booster immunisations were administered at week 2, 4 and 6 after the initial 
immunisation. Eggs were collected from all immunised chickens daily up to and 
including week 13. In addition, eggs were collected prior to the initial immunisation for 
the isolation of pre-immune antibodies. 
 
 
2.3.4.4 Isolation of chicken anti-VP2 peptide and chicken anti-VP2 antibodies 
Antibodies were isolated from chicken egg yolk according to Polson et al. (1985) with 
minor modifications (Goldring and Coetzer, 2003). Briefly, the egg yolk was separated 
from the egg white and rinsed under running tap water to remove excess egg white. The 
yolk was mixed with two volumes of IgY isolation buffer [100 mM Na-phosphate buffer, 
pH 7.6, 0.02% (w/v) NaN3] after which 3.5% (w/v) PEG Mr 6000 was added and 
dissolved with stirring. The sample was centrifuged (4420 x g, 20 min, RT) and the 
supernatant filtered through absorbent cotton wool. The filtrate volume was measured 
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and 8.5% (w/v) PEG Mr 6000 added and dissolved by stirring before centrifugation 
(12000 x g, 10 min, RT.) The supernatant was discarded and the pellet was dissolved in 
isolation buffer in a volume equal to the original egg yolk volume. To the dissolved pellet, 
12% (w/v) PEG 6000 was added and dissolved by stirring before centrifugation (12 000 
x g, 10 min, RT). The supernatant was discarded and the final pellet was resuspended 
in 1/6 of the original egg yolk volume of isolation buffer. Antibody concentration 
was determined by measuring A280 and using the extinction coefficient                =1.25 
(Goldring and Coetzer, 2003). 
 
 
2.3.4.5 Preparation of affinity matrices for antibody purification 
The VP2 peptides and purified VP2 expressed in P. pastoris were each coupled to 
affinity matrices in order to purify the chicken anti-VP2 peptide IgY and the chicken anti-
VP2 IgY respectively. Coupling was carried out under gravitational flow-rate. Peptides 
were coupled to SulfoLink® Coupling Resin according to the manufacturer's instructions. 
Briefly, the 50% slurry of SulfoLink® coupling resin (2 mL) was transferred to a Poly-Prep® 
Chromatography column and allowed to settle at RT. The storage buffer was drained 
and the column was equilibrated with four column volumes of coupling buffer (50 mM 
Tris-HCl, 5 mM EDTA-Na; pH 8.5). The peptide was reduced as before (Section 2.3.4.2) 
prior to coupling to the SulfoLink® coupling resin, made up to 2 mL with coupling buffer 
and incubated with the SulfoLink® coupling resin on an end-over-end rotator for 15 min 
at RT. The resin was allowed to stand and incubate for a further 30 min before 
draining and washing of the column with three column volumes of coupling buffer. 
The non-specific binding sites were blocked by incubating the resin with one column 
volume of 50 mM L-cysteine-HCl in coupling buffer on an end-over-end rotator for 
15 min at RT and a further 30 min in an upright position. The column was washed 
with six column volumes of 1 M NaCl before washing in storage buffer in which it 
was stored. 
 
Purified VP2 (5 mg) was coupled to AminoLink® Plus Resin according to the 
manufacturer's instructions. Briefly, the 50% resin slurry (2 mL) was transferred to a Poly-
Prep® Chromatography column and allowed to settle at RT. The storage buffer was 
drained and the resin bed equilibrated with three column volumes of coupling buffer 
(0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2). The VP2 sample was made up to 
6 mL with coupling buffer and the reductive amidation of the primary Schiff’s bases 
carried out with NaCNBH3 (50 mM final concentration) before incubation with the 
38 
 
resin overnight on an end-over-end rotator at 4°C. The contents were drained and 
the resin washed with 2 mL coupling buffer. The remaining sites were blocked by 
washing the resin with 2 mL quenching buffer (1 M Tris-HCl, pH 7.4) before a final 
round of reductive amidation of the Schiff’s bases with NaCNBH3 (50 mM final 
concentration) in 1 mL quenching buffer and incubation on an end-over-end rotator 
for 30 min at RT. The contents were drained and the column was washed with five 
column volumes of 1 M NaCl followed by washing with 3 mL storage solution (0.1 M 
sodium phosphate, 0.15 M NaCl, 0.05% (w/v) NaN3, pH 7.2) in which it was stored. 
 
 
2.3.4.6 Affinity purification of chicken anti-VP2 peptide and chicken anti-VP2 
antibodies 
The isolated chicken anti-VP2 peptide and chicken anti-VP2 antibodies (Section 2.3.4.4) 
were pooled and affinity purified on their respective affinity columns. Antibodies (60 mL) 
were filtered through Whatman no. 1 filter paper and circulated overnight in a reverse 
direction over the respective affinity matrices at RT. The column was washed with twenty 
column volumes of wash buffer [100 mM sodium phosphate buffer, 0.02% (w/v) NaN3, 
pH 6.5] and fractions (900 µL) eluted with elution buffer (100 mM glycine-HCI, pH 2.8) 
into a tube containing 100 µL neutralisation buffer (1 M sodium phosphate buffer, pH 
8.5). Elution fractions were monitored by measuring the A280 values and all fractions with 
absorbance values >0.4 were pooled and stored at 4°C after the addition of NaN3  to a 
final concentration of 0.1% (w/v).  
 
 
2.3.4.7 Indirect enzyme–linked immunosorbent assay (ELISA) to monitor antibody 
production 
An ELISA was used to monitor the production of chicken anti-VP2 peptide and chicken 
anti-VP2 antibodies over a 13 week period after the first immunisation and to 
determine the level of recognition of affinity purified antibodies. Antibody titres were 
monitored by coating Nunc 96 microtiter plate wells overnight at 4°C with 150 µL of 
1 µg/mL or 5 µg/mL peptide or recombinant VP2 in PBS. All unoccupied sites in the 
wells were blocked by incubating with 200 µL blocking solution [0.5% (w/v) BSA in 
PBS] for 1 h at 37°C and washed three times with 0.1% (v/v) PBS-Tween 20. Antibody 
titres from each week were determined by diluting antibodies in blocking solution from 
250 µg/mL to 0.001 µg/mL and incubating in the wells (100 µL) in duplicate for 2 h at 
37°C. Pre-immune, non-affinity purified and unbound antibodies were included as 
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controls to determine antibody levels of recognition. The plate was washed as before 
prior to the addition of 120 μl rabbit anti-IgY-HRPO conjugate (1:12 000 dilution) and 
incubated for 1 h at 37°C. The secondary antibody was removed and the plate washed 
as before. The chromogen/substrate solution [0.05% (w/v) ABTS, 0.0015% (v/v) H2O2 in 
0.15 M citrate-phosphate buffer, pH 5.0] (150 µL) was added to the wells and allowed 
to react in the dark for 30 - 45 min before reading the absorbance values at 405 nm 
using a FLUORStar Optima spectrophotometer (BMG Labtech, Germany). 
 
 
2.3.5 Analytical Biochemical Methods 
2.3.5.1 Agarose gel electrophoresis 
Agarose [1% (w/v)] was dissolved in TAE buffer (200 mM Tris-acetate buffer, pH 8.0, 
5 mM Na2-EDTA) by gentle heating. The gel solution was cooled down until the glass 
flask could be physically touched (±55°C) after which ethidium bromide was added to a 
final concentration of 0.5 µg/mL. Loading buffer [10 mM Tris-HCI buffer pH 8, 
0.03% (w/v) bromophenol blue, 0.03% (w/v) xylene cyanol FF, 60 mM EDTA, 60% (v/v) 
glycerol] was added to all samples in a 5:1 sample/loading buffer ratio. Electrophoresis 
of all DNA samples was performed at 60-100 V for 45 min and images were captured 
with a VersaDoc™ imaging system (BioRad, Hercules, USA) under UV light. 
 
 
2.3.5.2 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The SDS-PAGE analysis was performed according to LaemmLi (1970) using the Bio-Rad 
Mini Protean III® vertical slab electrophoresis apparatus. Protein samples which were 
analysed under reducing conditions were prepared by adding an equal volume of 
reducing treatment buffer [125 mM Tris-HCI buffer, 4% (w/v) SDS, 20% (v/v) glycerol, 
10% (v/v) -mercaptoethanol, pH 6.8] to the protein sample, vortexing and boiling for 
5 min. Protein samples analysed under non-reducing conditions were prepared by 
adding half the total volume of non-reducing treatment buffer [125 mM Tris-HCI buffer, 
4% (w/v) SDS, 20% (v/v) glycerol, pH 6.8] to the protein sample. Before loading 
samples on the gel, 25% (w/v) bromophenol blue was added (5 µL). Samples were 
subjected to electrophoresis at 18 mA per gel until the bromophenol blue tracker dye 
was about 0.5 cm from the bottom edge of the gel. The molecular mass marker 
sample was made up of phosphorylase b (97 kDa), BSA (68 kDa), ovalbumin 
(45 kDa), carbonic anhydrase (30 kDa), soybean trypsin inhibitor (21 kDa) and 
lysozyme (14 kDa). The marker was prepared by making up 5 mg/mL protein stocks 
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with treatment buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol, pH 6.8] 
and combining 80 µL of each of the protein stocks together with 20 µL reducing 
treatment buffer [10% (v/v) 2-mercaptoethanol in treatment buffer] and 25% (w/v) 
bromophenol blue. The marker was boiled for 2.5 min and 4 µL loaded per gel. 
Since the relative mobility of a protein is inversely proportional to its log molecular 
mass, a calibration curve was generated from the known protein molecular masses 
to determine unknown protein sizes (Figure 2.5). A PageRuler™ Pre-stained Protein 
Ladder (Fermentas, Luthuania) was also used. 
 
 
 
 
 
 
 
 
Figure 2.5 Calibration curve for determining unknown protein molecular masses. The 
molecular mass proteins: phosphorylase b (97 kDa), BSA (68 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (30 kDa), soybean trypsin inhibitor (21 kDa) and lysozyme (14 kDa), 
were separated by 10% reducing SDS-PAGE and their relative mobility plotted against their 
log molecular weight. The equation of the trend line is y = -7.062x + 15.424 and the 
correlation co-efficient is 0.9899. 
 
 
Silver staining 
Protein bands were visualised by staining with silver nitrate, Coomassie Blue R-250 
or Oriole™ Fluorescent Gel Stain (Bio-Rad, USA). The silver nitrate staining method 
was carried according to Blum et al. (1987) on an orbital shaker at RT using 
thoroughly cleaned glassware. Gels were immersed in fixing solution [50% (v/v) 
methanol, 12% (v/v) acetic acid, 0.5% (v/v) 37% formaldehyde] for 1 hour or 
overnight and placed in washing solution [50% (v/v) ethanol] (3 × 20 min). Gels were 
incubated for 1 min in pre-treatment solution [0.02% (w/v) sodium thiosulfate 
pentahydrate (Na2S2O3.5H2O) and rinsed in distilled water (3 × 5 min) before 
soaking in impregnation solution [0.2% (w/v) silver nitrate, 0.75% (v/v) 37% 
formaldehyde] for 20 min. The gel was rinsed in distilled water (2 × 20 s) and 
incubated in developing solution [60 g/L Na2CO3, 0.5% (v/v) 37% formaldehyde, 
0.004% (w/v) Na2S2O3.5H2O] until the first protein bands became visible. 
Development was allowed to proceed in distilled water and was stopped by 
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immersing the gel in stopping solution [50% (v/v) methanol, 12% (v/v) acetic acid] 
for 10 min. The gel was transferred to 50% (v/v) methanol before the image was 
captured with the VersaDoc™ imaging system (Bio-Rad, USA). 
 
 
Coomassie Brilliant Blue R-250 stain 
For the Coomassie R-250 stain, gels were placed in  Coomassie stain [0.125% (w/v) 
Coomassie Blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid], destained in 
Destain I [50% (v/v) methanol, 10% (v/v) acetic acid] and Destain II [7% (v/v), 
5% (v/v)]. Gels were imaged using the Bio-Rad VersaDoc™ imaging system.  
 
 
Oriole™ Fluorescent Gel Stain 
Gels were also stained with the Oriole™ Fluorescent Gel Stain (BioRad, USA) 
according to the manufacturers’ instructions. The Oriole™ stain can detect purified 
proteins at extremely low concentrations of approximately 0.001-0.002 µg. 
 
 
2.3.5.3 Western blotting 
Proteins were electro-transferred onto nitrocellulose membrane for western blotting 
after separation by SDS-PAGE using a wet blotter (BioRad, Hercules, USA). This 
was done by sandwiching the gel and nitrocellulose membrane between two sets of 
blotting paper and one set of sponges in a blotting cassette. The gel, nitrocellulose 
membrane and blotting paper were soaked in blotting buffer [20 mM Tris-HCl, 
192 mM glycine, 20% (v/v) methanol, 1% (w/v) SDS] prior to transfer which was 
conducted at 40 mA for 16 h. The membrane was transiently stained for 5 min with 
Ponceau S stain [0.1% (w/v) Ponceau S, 1% (v/v) glacial acetic acid] to determine 
the quality of protein transfer and to mark the molecular weight marker positions 
with a pencil (if an unstained marker was used). The membrane was destained in 
distilled water containing a few drops 1 M NaOH solution. The nonspecific sites on 
the nitrocellulose membrane were blocked with 5% (w/v) non-fat milk in Tris-
buffered saline (TBS) (20 mM Tris, 200 mM NaCI, pH 7.4) for 1 h with gentle 
shaking. Thereafter the membrane was washed with TBS (3 x 5 min) and incubated 
for 2 h with primary antibody [1:2 000 mouse anti-His tag monoclonal antibody or 
100 µg/mL chicken anti-VP2 peptide or chicken anti-VP2 antibodies] made up in 
0.5% (w/v) BSA-TBS and washed as before in TBS (3 x 5 min). Following washing, 
42 
 
the membrane was incubated in secondary antibody [horse anti-mouse-HRPO 
(1:12 000) or rabbit anti-chicken-HRPO (1:12 000)] in 0.5% (w/v) BSA-TBS for 1 h 
and again washed in TBS (3 x 5 min). Finally the nitrocellulose membrane was 
immersed in chromogen/substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 
0.1% (v/v) methanol, 0.0015% (v/v) H2O2 in TBS], allowed to develop in the dark 
and placed in distilled water once protein bands were clearly visible. 
 
 
2.3.5.4 Quantification of purified protein 
Purified VP2 samples were quantified using the BCA™ Protein Assay kit (Pierce, 
USA) according to the manufacturer’s instructions in a Nunc™ 96 microtiter plate. 
The absorbance readings (A562) of standard BSA samples and samples of unknown 
protein concentration were determined using a FLUORStar Optima 
spectrophotometer (BMG Labtech, Offenburg, Germany) and used to generate a 
standard curve for the quantification of protein (Figure 2.6). Alternatively the 
quantification was carried out by running the BSA standard samples on reducing 
SDS-PAGE alongside the protein samples to be determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Standard curve for the quantification of proteins. The BCA™ Protein Assay 
Kit was used to generate the curve using BSA as protein standards ranging from 0.125 – 
2.0 mg/mL. The equation of the trend line is y = 0.4989x + 0.0381 and the correlation 
coefficient is 0.9949. 
 
 
2.4 RESULTS 
2.4.1 Bacterial Expression of VP2 
2.4.1.1 Expression of VP2 using pGEX-4T-1 
Expression of VP2 in pGEX-4T-1 was attempted in 2xYT broth by IPTG induction. 
Genes in pGEX-4T-1 are expressed as a protein with a GST-tag which has a 
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molecular mass of 26 kDa. The VP2 protein has a molecular mass of 47 kDa 
therefore the expression of VP2 in pGEX-4T-1 is expected to yield a fusion protein 
with a molecular mass of 73 kDa. The E. coli cell lysates (20 µg/well) were analysed 
for VP2 expression by SDS-PAGE (Figure 2.7). Although uninduced lysate (lane 1) 
show a similar profile as the induced lysate (lane 2) the band intensity in the 
uninduced lysates was lower than the induced sample. Expression of VP2 was 
therefore unsuccessful in this system even after optimisation of expression 
conditions such as IPTG concentration, expression temperature and time. Western 
blotting using chicken anti-GST tag antibodies confirmed the lack of expression 
when this system was used (result not shown).  
 
 
 
 
 
 
 
Figure 2.7 Expression analysis of pGEX-4T-1-VP2 construct on a 10% reducing SDS-
PAGE stained with Coomassie blue R-250. Lane M, molecular weight marker; lane 1, 
uninduced pGEX-4T-1-VP2 lysate and lane 2, induced pGEX-4T-1-VP2 lysate. Arrow 
indicates Mr at which VP2 is expected. 
 
 
2.4.1.2 Expression of VP2 using pET-32a 
Expression of the pET-32a recombinants was performed by both auto-induction in 
Terrific broth (Figure 2.8A) and IPTG induction in 2xYT medium (Figure 2.8B). 
Genes cloned in the pET-32a system are expressed with an N-terminal Trx-His tag 
which has a molecular mass of 17 kDa. Therefore the expected size for the 
recombinant fusion protein expressed in this system was 64 kDa. The E. coli 
BL21(DE3) cells were used as a control for the expression of VP2 in Terrific broth 
(Figure 2.8A, lane 1). The His-tagged VP2 was successfully expressed as a 64 kDa 
fusion protein (Figure 2.8A, lane 2) as expected. High molecular mass proteins at 
the top of the gel were also observed in the lysate. For the IPTG-induced 
expression, a non-induced lysate was used as a control (Figure 2.8B, lane 1). The 
44 
 
IPTG induced expression was unsuccessful as the induced lysate demonstrated no 
expression of a 64 kDa VP2 protein (Figure 2.8B, lane 2). In addition, western 
blotting was used to confirm that the 64 kDa protein band observed in the auto-
induced expression was the recombinant Trx-His-VP2 fusion protein (Figure 2.8C). 
Due to the unavailability of chicken anti-VP2 antibodies at the time, mouse anti-His 
tag antibodies were used. The mouse anti-His tag antibodies did not detect any 
proteins in the control lysate (Figure 2.8C, lane 1), but recognised the 64 kDa 
protein band corresponding to VP2 fusion protein as well as high molecular mass 
proteins (Figure 2.8C, lane 2). 
 
 
 
 
 
 
 
 
 
Figure 2.8 Analysis of VP2 expression using the pET-32a vector in E. coli BL21(DE3) 
cells. (A) 10% reducing SDS-PAGE analysis of VP2 auto-induced expression in Terrific 
broth. (B) 10% reducing SDS-PAGE analysis of VP2 IPTG induced expression. (C)  Western 
blot analysis of VP2 auto-induced expression detected with a monoclonal mouse anti-His tag 
antibody. Lane M, molecular weight marker; lane 1, E. coli BL21(DE3) control lysate (A and 
C) and non-induced lysate (B) and lane 2, auto-induced pET-32a-VP2 lysate (A and C) and 
IPTG induced lysate (B). Arrows indicate expressed proteins. 
 
 
The solubility of the expressed VP2 sample was determined by separating the 
bacterial cell pellet (insoluble fraction, I) and supernatant (soluble fraction, S). When 
analysed on reducing SDS-PAGE, the band corresponding to the fusion protein was 
only observed in the insoluble fraction suggesting that the protein was expressed as 
inclusion bodies (Figure 2.9A). In an attempt to improve the solubility of VP2, the 
expression was carried out at different temperatures below 37°C (Figure 2.9B). The 
VP2 expression at 16°C and 25°C was negligible with a small degree of VP2 visible 
only in the insoluble fraction (Figure 2.9B). Even though the expression level was 
high at 30°C, the fusion protein was still in the insoluble fraction (Figure 2.9B). 
Changing the temperature conditions did not improve the solubility of VP2, therefore 
VP2 expression was continued at 37°C. 
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Figure 2.9 Analysis of VP2 solubility after expression at different temperatures 
analysed by reducing 10% SDS-PAGE stained with Coomassie Blue R-250. Expression 
was performed at 37°C (A) 16°C, 25°C and 30°C (B). Key: molecular weight marker (M), 
E. coli BL21(DE3) control cell lysate (C); soluble (S) and insoluble (I) fractions. Arrows 
indicate VP2. 
 
 
The inclusion bodies were subjected to three washes in 2 M urea prior to 
solubilisation in 8 M urea (Figure 2.10). Some of the VP2 protein was released 
during the first two washes (lanes 2 and 3), but not in the last wash (lane 4). The 
washed inclusion bodies were solubilised in 8 M urea and thereafter centrifuged to 
separate the insoluble aggregates (lane 5) and solubilised protein (lane 6). 
Recombinant VP2 was successfully solubilised as shown by the presence of the 
64 kDa fusion protein in the solubilisation supernatant. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Reducing SDS-PAGE (10%) analysis of VP2 solubilisation stained with 
Coomassie blue R-250. Lane M, molecular mass marker; lane 1, VP2 insoluble fraction; 
lanes 2 to 4, 2 M urea washes; lane 5, insoluble aggregates after 8 M urea solubilisation and 
lane 6, solubilised proteins after 8 M urea solubilisation. Arrows indicate VP2 protein. 
46 
 
2.4.2 Purification of VP2 expressed in E. coli 
2.4.2.1 Affinity purification of insoluble Trx-His tagged recombinant VP2 
The solubilised sample containing VP2 was purified on a Ni-NTA His-Bind affinity 
column under denaturing conditions and the purification steps were analysed by 
reducing SDS-PAGE and western blotting (Figure 2.11). An E. coli BL21(DE3) cell 
lysate (lane 1) and a VP2 solubilised fraction (lane 2) were separated alongside the 
purification fractions for comparison. The VP2 bound poorly to the affinity matrix as 
evidenced by the presence of VP2 in the unbound fraction (Figure 2.11A, lane 3). 
Proteins, including some VP2, were also released during the washing step (Figure 
2.11A, lane 4) although a considerable amount of VP2 was released during elution 
with imidazole, with co-purification of bacterial proteins (Figure 2.11A, lanes 5-7). In 
the western blot analysis, mouse anti-His tag antibodies did not detect any proteins 
in the E. coli BL21(DE3) cell lysate control (Figure 2.11B, lane 1). The VP2 protein 
at the expected size of 64 kDa and high molecular mass proteins were detected in 
the solubilised, unbound and wash fractions (Figure 2.11B, lanes 2-4). The VP2 
purification under denaturing conditions was considered an unfavourable method of 
purification because eluted proteins are in a denatured state and require further 
steps to refold the protein. 
 
 
 
 
 
 
 
Figure 2.11 Analysis of VP2 purification under denaturing conditions on a Ni-NTA 
His-Bind matrix. (A) Reducing 10% SDS-PAGE stained with Coomassie Blue R-250. 
(B) Western blot using a monoclonal mouse anti-His tag antibody. Lane 1, E. coli BL21 
(DE3) control lysate; lane 2, solubilised VP2; lane 3, unbound fraction; lane 4, wash fraction, 
lanes 5-7, VP2 elution fractions. Arrows indicate VP2 and high molecular mass proteins. 
 
 
To obtain correctly folded VP2 for subsequent use, the solubilised sample 
containing VP2, was refolded on a Ni-NTA His-Bind affinity column. Denatured VP2 
was subjected to refolding during the washing step by using a descending 
concentration gradient from 8 M urea to 0 M urea. Eluted fractions were analysed by 
reducing SDS-PAGE (Figure 2.12A) and western blotting (Figure 2.12B). An E. coli 
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BL21 (DE3) cell control lysate (Figure 2.12A, lane 1) and VP2 expression sample 
(Figure 2.12A, lane 2) were analysed alongside the purified refolded VP2 fractions 
(Figure 2.12A, lanes 3-8). In the western blot the mouse anti-His tag antibody 
detected the fusion protein in the expression sample (Figure 2.12B, lane 2), 
unbound fraction (Figure 2.12B, lane 3), wash fraction (Figure 2.12B, lane 4) and 
the refolded sample (Figure 2.12B, lane 5). High molecular mass proteins were also 
recognised by the monoclonal mouse anti-His tag antibody (Figure 2.12B, lane 2) 
and in the refolded VP2 fractions (Figure 2.12B, lanes 5 and 6). The non-reduced 
refolded VP2 fraction (Figure 2.12B, lane 6) was detected at a size larger than the 
reduced refolded fraction which indicates the protein was successfully refolded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Analysis of VP2 on-column refolding purification using Ni-NTA His-Bind 
resin.
 
(A) 10% reducing SDS-PAGE stained with silver nitrate. Lane M, molecular weight 
marker; lane 1, E. coli BL21(DE3) cell control lysate; lane 2, VP2 expression sample; lanes 3 
to 8, VP2 purified refolded fractions.  (B) Western blot using mouse anti-His tag antibodies. 
Lane M, molecular weight marker; lane 1, E. coli BL21(DE3) cell control lysate; lane 2, VP2 
expression sample; lane 3, unbound fraction; lane 4, wash fraction; lane 5, reduced refolded 
VP2 and lane 6, non-reduced refolded VP2. Arrows indicate VP2 and high molecular mass 
proteins. 
 
 
2.4.2.2 Cation-exchange chromatography of VP2 wash fractions 
Ion-exchange chromatography is occasionally used as a secondary purification step 
following affinity chromatography to obtain pure proteins for protein crystallisation 
(Dennison, 2003)  or for further purification of antibodies (Liu et al., 2010). Since 
most of the VP2 protein was released during the washing step with minimal 
contaminating proteins during purification under denaturing conditions, the wash 
fractions were retained and dialysed in two changes of IEC buffer for further 
purification using cation exchange chromatography. Protein elution was observed 
after the addition of 0.5 M NaCl as shown by higher A280 readings of the fractions 
(Figure 2.13A). The addition of 0.05 M NaCl and 0.1 M NaCl appears to release low 
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quantities of the protein as indicated by the low A280 readings. Various elution 
fractions from the peaks observed were further analysed by SDS-PAGE (Figure 
2.13B) as indicated by the arrows below the elution profile. 
 
The eluted fractions were analysed along with the dialysed VP2 sample (lane 1). 
Fraction 13 (lane 2) and 15 (lane 3) from the first peak contained some VP2 at the 
expected size of 64 kDa, as well as contaminating proteins and high molecular mass 
proteins. Fractions 25 (lane 4) and 27 (lane 5) analysed after the addition of 0.05 M 
NaCl showed a light protein band above 68 kDa. Fractions 37 (lane 6) and 39 
(lane 7) eluted after the addition of 0.1 M NaCl, contained VP2, some high molecular 
mass proteins and other contaminating proteins around 30 kDa. Fraction 57 (lane 8) 
and 59 (lane 9) from the second peak analysed after the addition of 0.5 M NaCl  
contained VP2 at the expected size of 64 kDa as well as some high molecular mass 
proteins. 
 
2.4.2.3 Electro-elution of VP2 
In addition to the expression of the VP2 protein, high molecular mass proteins were 
also observed (Figure 2.8A and C) and co-purified with VP2 on a Ni-NTA His-Bind 
affinity column (Figure 2.11). The high molecular mass proteins were therefore 
hypothesised to be VP2 multimers or incorrectly folded VP2. To further identify this, 
both VP2 (64 kDa) and the high molecular mass proteins were excised from SDS-
PAGE gels, electro-eluted and analysed by SDS-PAGE (Figure 2.14). An E. coli 
BL21(DE3) cell control lysate (lane 1) and expression sample (lane 2) were 
analysed alongside the electro-eluted VP2 sample (lane 3) and the high molecular 
mass electro-eluted sample (lane 4). The electro-eluted VP2 sample was observed 
at the expected size of 64 kDa (lane 3). The 64 kDa protein band was also observed 
when the high molecular mass protein was electro-eluted (lane 4). The electro-
elution of the high molecular mass proteins was repeated several times with the 
same observable result on SDS-PAGE (lane 4). Since analysis of the high molecular 
mass proteins on SDS-PAGE reduced some of the proteins to a 64 kDa protein and 
mouse anti-His tag monoclonal antibodies used to detect VP2 expression 
recognised the high molecular mass proteins (Figure 2.8C, 2.11B and 2.12B), these 
proteins were believed to be VP2 multimers. Although the VP2 protein was 
successfully expressed in the E. coli expression system, purification of sufficient 
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quantities was difficult. Therefore the P. pastoris expression system was also used 
to increase the yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Analysis of IEC purification of Trx-His tagged recombinant VP2. (A) 
Elution profile of VP2 purification on SP-Sephadex C-25 cation exchange chromatography 
column (25 x 150 mm; 30 mL/h). A step-wise gradient of NaCl was applied at 23 mL (0.05 
M), 35 mL (0.1 M) and 47 mL (0.5 M) elution volume. The arrows indicate the fractions used 
for SDS-PAGE analysis. (B) Analysis of IEC elution fractions by reducing 10% SDS-PAGE 
stained with silver nitrate. Lane M, molecular weight marker; lane 1, dialysed VP2 sample; 
lanes 2-9 contain the eluted fractions as indicated. 
 
 
 
 
 
 
 
 
 
Figure 2.14 Analysis of the electro-eluted VP2 and high molecular mass proteins. 
Samples were separated on a 10% reducing SDS-PAGE gel and stained with silver nitrate. 
Lane M, molecular weight marker; lane 1, E. coli BL21(DE3) cell lysate; lane 2, VP2 
expression sample; lane 3, electro-eluted VP2 sample; lane 4, electro-eluted high molecular 
mass sample. Arrows indicate electro-eluted proteins. 
50 
 
2.4.3 VP2 expression in P. pastoris 
The VP2 coding region was previously cloned into the pGEX-4T-1 and pET-32a 
expression vector and transformed into E. coli JM109 BL21 and BL21(DE3) cells, 
respectively. The VP2 coding region from recombinant pGEX-4T-1 plasmid was 
used for sub-cloning into the pPIC9 vector. This was achieved by performing a DNA 
plasmid miniprep isolation and double restriction digest with EcoRI and NotI to 
release the VP2 insert DNA (Figure 2.15). The pPIC9 expression vector was also 
isolated (lane 3) and subjected to a double restriction digest with EcoRI and NotI to 
prepare the vector for ligation with the VP2 insert DNA. Uncut recombinant pGEX-
4T-1 plasmid containing the VP2 gene was observed as a single band at 
approximately 5 kb (lane 1). An uncut plasmid usually runs as three bands which 
correspond to the three conformations of DNA namely, supercoiled, linear and 
circular DNA. However, in this study uncut DNA was only visible as a single band 
which could be the result of low DNA concentration. The double restriction digestion 
of recombinant pGEX-4T-1 with EcoRI and NotI released two bands corresponding 
to vector (5 kb) and insert DNA at 1.2 kb (lane 2). The purified linearised vector was 
observed at 8 kb as expected (lane 4). 
 
 
 
 
 
 
 
 
 
Figure 2.15 Analysis of plasmid DNA miniprep isolation and double restriction 
digestion of recombinant pGEX-4T-1-VP2 and non-recombinant pPIC9 expression 
vector. The recombinant pGEX-4T-1-VP2 and non-recombinant pPIC9 expression vector 
was restriction digested with EcoRI and Not I and analysed on a 1% (w/v) agarose gel 
stained with ethidium bromide. Lane M, MassRuler DNA ladder; lane 1, uncut pGEX-4T-1-
VP2; lane 2, cut pGEX-4T-1-VP2; lane 3, uncut pPIC9 and lane 4, cut pPIC9. 
 
 
The VP2 insert DNA was ligated to the pPIC9 expression vector and transformed 
into E. coli JM109 cells. Colonies were screened for recombinants by colony PCR 
using AOX vector primers (Figure 2.16). The AOX primers are expected to amplify a 
490 bp fragment for a non-recombinant plasmid, therefore for a recombinant 
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plasmid, the amplicon size should be 490 bp plus the size of the VP2 insert DNA, 
i.e. 1.2 kb. Of the two colonies analysed, both were recombinant for the 1.2 kb VP2 
gene as seen by the amplification of a 1.7 kb fragment (lanes 1 and 2). 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Analysis of colony PCR screening of pPIC9-VP2 recombinants. Colonies 
were screened for recombinants using AOX vector primers and analysed on a 1% (w/v) 
agarose gel stained with ethidium bromide. Lane M, MassRuler DNA ladder; lanes 1 and 2, 
colonies 1 and 2. 
 
 
A DNA miniprep isolation was performed on the E. coli cells containing the pPIC9-
VP2 recombinant plasmid and linearised with SacI in preparation to be integrated 
into the P. pastoris genome (Figure 2.17). The DNA isolation (lane 1) and linearised 
DNA (lane 2)  was observed at the expected size of approximately 10 kb. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Analysis of SacI digestion of pPIC9-VP2 recombinant plasmid. The 
restriction digested pPIC9-VP2 recombinant was analysed on a 1% (w/v) agarose gels 
stained with ethidium bromide. Lane M, MassRuler DNA ladder; lane 1, uncut pPIC9-VP2 
and lane 2, cut pPIC9-VP2 linearised with SacI.  
 
 
The linearised pPIC9-VP2 recombinant plasmid was transformed into P. pastoris 
GS115 yeast cells and screened for recombinants by colony PCR using the 
universal AOX primers (Figure 2.18). Of the two colonies that grew, one gave a DNA 
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fragment of approximately 500 bp (lane 1) whereas a size of 1.9 kb is expected for a 
successful clone. A DNA fragment could not be clearly observed for the second 
colony (lane 2) and the PCR therefore gave inconclusive results. 
 
 
 
 
 
 
 
 
Figure 2.18 Colony PCR of P. pastoris GS115 cells transformed with SacI-linearised 
recombinant pPIC9 plasmids containing VP2. In order to determine if integration into the 
genomic DNA was successful, samples were analysed on a 1% (w/v) agarose gel and 
stained with ethidium bromide. Lane M, MassRuler DNA ladder; lane 1 and 2, PCR products 
after amplification with AOX primers of colonies 1 (lane 1) and 2 (lane 2). 
 
 
Although the PCR results were inconclusive to determine whether pPIC9-VP2 was 
successfully integrated into the P. pastoris genome, a decision was made to 
continue with expression to determine the success of the transformation. Therefore, 
the colony was used to inoculate growth medium and induced for expression by 
daily supplementation with methanol. Protein expression was analysed by SDS-
PAGE and visualised with silver nitrate staining (Figure 2.19). The VP2 was 
successfully expressed at the expected size of 47 kDa along with high molecular 
mass proteins and an 80 kDa protein (lane 2). 
 
Three-phase partitioning was used as an initial concentrating and purification step 
after VP2 expression in the P. pastoris system (Figure 2.19). The TPP method uses 
t-butanol and ammonium sulfate as a salting-out type fractionation method which is 
useful for precipitating out proteins in solution. Proteins in the induced supernatant 
were efficiently precipitated using TPP as indicated by the prominent smear of high 
molecular mass proteins (lane 3). 
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Figure 2.19 Analysis of VP2 expression in P. pastoris following concentration of the 
expressed supernatant by TPP. Samples were separated by reducing 10% SDS-PAGE 
and stained with silver nitrate. Lane M, molecular weight marker; lane 1, non-induced 
expression supernatant; lane 2, induced expression supernatant; lane 3, expression 
supernatant concentrated using TPP. Red arrows indicate expressed proteins and the black 
arrow indicates VP2 after TPP. 
 
 
In order to purify VP2 from other contaminating proteins, MEC using a Sephacryl 
S300 chromatography column which has a fractionation range of 10 to 1500 kDa 
(Dennison, 1999) was used. The resin sufficiently separated the calibration proteins 
into four distinct peaks (Figure 2.20A) and was therefore considered a suitable resin 
for separating the47 kDa and high molecular mass VP2 proteins from the 80 kDa 
contaminating proteins shown in Figure 2.19. Two major peaks were observed when 
the sample obtained after TPP containing VP2 was separated on Sephacryl S300 
(Figure 2.20B). Reducing SDS-PAGE analysis of the two fractions, followed by 
staining with Oriole™ Fluorescent Gel Stain (Bio-Rad) that is able to detect proteins 
at a concentration as low as 0.002 µg, is shown in Figure 2.20C. Lane 1 is the VP2 
sample which was loaded onto the MEC column. Fractions from peak one (lanes 2 
to 6) contained only high molecular mass proteins and therefore separation of these 
proteins was successful. Analysis of peak two (lanes 7 to 12) demonstrated 
unsuccessful separation as VP2 at 47 kDa co-eluted with contaminating proteins. 
Since it was believed that the high molecular mass proteins in the first peak were 
VP2 multimers or incorrectly folded VP2, these fractions were pooled for later 
analysis. 
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Figure 2.20 Analysis of P. pastoris expressed VP2 purification on a Sephacryl S300 
MEC column. (A) Elution of calibration proteins: blue dextran (2000 kDa), BSA (68 kDa), 
ovalbumin (45 kDa) and myoglobin (16.7 kDa), were used to calibrate the column (25 x 
840 mm, flow rate 25 mL/h, MEC buffer). (B) Elution profile of VP2 separation on Sephacryl 
S-300. (C) Analysis by 10% reducing SDS-PAGE of elution peaks stained with Oriole™ 
Fluorescent Gel Stain. Lane M, molecular mass marker; lane 1, VP2 sample before 
separation on MEC; lanes 2-6, elution volume 135, 140, 145, 150 and 155 from peak 1; 
lanes 7-12, elution volume 208, 212, 221, 226, 233 and 236 from peak 2. The red arrow 
indicates the VP2 high molecular mass proteins which were efficiently separated from the 
contaminating proteins and the 47 kDa VP2 protein (black arrows) which could not be 
efficiently separated from one another. 
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2.4.4 VP2 peptide selection  
The VP2 peptides were designed for raising chicken anti-peptide antibodies that 
would be used to identify possible IBDV receptor(s). The VP2 amino acid sequence 
(Met1-Ala441) was analysed with the Predict7™ program (Cármenes et al., 1989) to 
determine ideal peptide sequences according to hydrophilicity, surface probability, 
flexibility and antigenicity parameters  (Figure 2.21). From the plot three peaks were 
considered good candidates which are around residues 31, 201 and 401, which all 
display high hydrophilicity. Antigenicity is relatively low throughout the sequence 
because this parameter is based on information on the antigenicity of a very small 
number of proteins (Cármenes et al., 1989). For the production of chicken anti-VP2 
peptide antibodies two peptide sequences with high hydrophilicity and surface 
probability were selected: residues 26 to 39 and 192 to 202 (Table 2.2 and Figure 
2.22). In addition to the Predict7™ software, the Cn3D™ program was used to 
determine the location of the two peptides on the VP2 crystal structure (Figure 
2.22B and D). Both peptides were shown to be located in a random loop on the 
outer surface of the VP2 protein. 
 
Of the two peptides selected for antibody production, the first peptide sequence, 
VP2-1, consists of 14 amino acid residues which span amino acid residues 26-39 
(Figure 2.22A). Peptide VP2-1 demonstrated high hydrophilicity and surface 
probability towards the centre of the sequence. Antigenicity is low toward the N-
terminus and higher toward the centre and C-terminus. Flexibility is constant 
throughout the sequence. Since the centre of the peptide sequence was higher for 
all parameters it was decided that the addition of a cysteine residue to either 
terminus would be acceptable. Therefore a cysteine residue was added at the C-
terminus for carrier conjugation (Table 2.2). The second peptide, VP2-2, consists of 
11 amino acids which span amino acid residues 192-202 (Figure 2.22C). The VP2-2 
peptide demonstrates low hydrophilicity and surface probability at the N-terminus 
and high toward the C-terminus. Flexibility and antigenicity were relatively constant 
throughout the sequence although antigenicity is slightly higher toward the C-
terminus. A cysteine residue was therefore added at the N-terminus for carrier 
conjugation and since VP2-2 contained an internal cysteine residue, it was replaced 
by α-aminobutyric acid (Table 2.2) to avoid conjugation of the carrier to the centre of 
the peptide which would prevent exposure of the entire epitope to the immune 
system for antibody production.  
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Figure 2.21 Analysis of the VP2 amino acid sequence (residues 1-441) using Predict7™. The amino acid sequence is shown in 
(A) and the Predict7 analysis shown in (B). Peptides were selected based on the four paramaters: hydrophilicity, surface probability, 
flexibility and antigenicity. The regions highlighted by the black rectangles indicate the peptides used for immunisation (for a detailed 
plot see Figure 2.22). 
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Table 2.2  Amino acid sequences of the synthetic peptides and their 
residue positions within the VP2 sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.22 Epitope prediction plots of selected VP2 peptides and their respective 
positions on the VP2 3D structure. (A) VP2-1 amino acid sequence. (B) VP2 3D structure 
demonstrating the VP2-1 peptide sequence. (C) VP2-2 amino acid sequence. (D) VP2 3D 
structure demonstrating the VP2-2 peptide sequence. Peptides were selected on the basis of 
four parameters: hydrophilicity, surface probability, flexibility and antigenicity using 
Predict7™ software (Cármenes et al., 1989). The VP2 3D structure was viewed using 
Cn3D™ software to show the localisation of the selected peptides on the structure. The P-
domain is displayed in blue and the S and B domains are displayed in pink. The selected 
peptides are depicted in yellow.  
 
  
Peptide code Sequence
a
 Residue no. 
VP2-1 ASIPDDTLEKHTLRC  26-39 
VP2-2 CKMVATAbuDSSDR
b
  192-202 
a Cys in bold was added for carrier conjugation 
b α-aminobutyric acid (Abu) was used to replace the internal Cys-residue  
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2.4.5 Production and purification of chicken anti-VP2 peptide antibodies 
Two pairs of chickens were each immunised with either the VP2-1 or VP2-2 peptide 
carrier protein conjugate and the immune response monitored over a 13 week 
period (Figure 2.23). For chicken 1 immunised with VP2-1, an initial peak of 
antibody production was observed after the first booster immunisation at week 2 
followed by a rapid increase in antibodies after the second booster at week 4. 
Antibody production slowly decreased thereafter and remained relatively constant 
after the third booster immunisation at week 6 before slowly decreasing again 
(Figure 2.23A). In chicken 2 immunised with VP2-1, the production of antibodies 
increased considerably from week 3 up to week 6 and slowly began decreasing in 
subsequent weeks (Figure 2.23A). Chickens immunised with VP2-2 peptide 
conjugate showed no immune response which remained constant throughout a 13 
week period despite receiving three booster immunisations (Figure 2.23B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23 ELISA plot demonstrating chicken anti-VP2-1 and chicken anti-VP2-2 
peptide antibody production over a 13 week period. Two chickens (chicken 1 and 
chicken 2) were each immunised with either a VP2-1 or VP2-2 peptide-rabbit albumin 
conjugate and the antibody production monitored. ELISA plates were coated with 1 µg/mL 
VP2-1 or VP2-2 peptide and probed with 100 µg chicken anti-VP2-1 or chicken anti-VP2-2 
peptide antibodies respectively, followed by detection with rabbit anti-chicken IgY-HRPO 
conjugate (1:12 000) followed by ABTS/H2O2 chromogen-substrate. Arrows indicate weeks 
at which booster immunisations were administered. Each plot is the average absorbance 
reading at 405 nm of duplicate experiments. 
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Titres for antibodies produced over time by chickens immunised with VP2-1 were 
monitored by ELISA (Figure 2.24A and B). For the first chicken (Figure 2.24A) 
antibody titres peaked from week 4 and continued to increase up to week 6.  Titres 
decreased slightly in week 7 to week 13. For chicken 2 (Figure 2.24B) the antibody 
titres increased from week 3 to week 6 and again slowly decreased from week 7 to 
week 13. Antibodies produced in week 6 demonstrated the best antibody titres while 
chicken 1 produced higher antibody titres than chicken 2.  
 
Although it was observed that immunising chickens with the VP2-2 peptide-
conjugate produced low levels of antibodies, the isolated antibody titres from 
alternate weeks were in addition analysed on ELISA (Figure 2.25A and B) and the 
peptide coating concentration increased from 1 µg/mL to 5 µg/mL. Analysis of 
antibodies produced in chicken 1 (Figure 2.25A) and chicken 2 (Figure 2.25B) 
demonstrated low antibody titres much like the non-immune control. A small 
increase was, however, observed from weeks 8 to 11. Antibodies isolated for VP2-2 
peptide were therefore not affinity purified due to the relatively low level of chicken 
anti-VP2-2 peptide antibody production although the non-purified antibodies from 
weeks 8 to 11 were retained for possible future use. 
 
 
 
 
 
 
 
 
 
 
Figure 2.24 ELISA analysis of chicken anti-VP2-1 peptide antibody titres. (A) Anti-
VP2-1 peptide antibody titres produced by chicken 1 (A) and chicken 2 (B) for week 0 to 13 
after first immunisation. ELISA plates were coated with 1 µg/mL VP2-1 peptide and probed 
with a dilution series of antibodies (250 µg/mL – 0.001
 
µg/mL) isolated from each week 
before detection with rabbit anti-chicken  IgY-HRPO conjugate (1:12 000) followed by 
ABTS/H2O2 chromogen-substrate. Each plot is the average absorbance reading at 405 nm of 
duplicate experiments. 
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Figure 2.25 ELISA analysis of chicken anti-VP2-2 peptide antibody titres. Chicken 
anti-VP2-2 peptide antibody titres produced by chicken 1 (A) and chicken 2 (B) for alternate 
weeks from week 0 to week 11. ELISA plates were coated with 5 µg/mL VP2-2 peptide and 
probed with a dilution series of antibodies (250 µg/mL – 0.001
 
µg/mL) isolated from each 
week before detection with rabbit anti-chicken IgY-HRPO conjugate (1:12 000) followed by 
ABTS/H2O2 chromogen-substrate. Each plot is the average absorbance reading at 405 nm of 
duplicate experiments. 
 
 
The isolated antibodies from the two chickens immunised with the VP2-1 peptide-
conjugate were both pooled according to weeks 3-6, weeks 7-11 and 12-13 and 
affinity purified on a peptide affinity column. The eluted fractions were monitored by 
measuring absorbance at 280 nm (Figure 2.26). Antibodies from weeks 7-11 were 
affinity purified in two batches due to the large sample volume and produced the 
highest concentration of antibodies as indicated by the highest A280 readings. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.26 Elution profiles of affinity purified chicken anti-VP2-1 peptide 
antibodies. Pooled, isolated antibodies from weeks 3 to 6, weeks 7 to11 and weeks 12 to 13 
were affinity purified.. The arrow indicates the point at which elution began using 0.1 M 
glycine-HCl and the asterisk (*) indicates points measured at the detection limit of the 
spectrophotometer.  
volume (mL) 
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Recognition of the VP2-1 peptide in an ELISA of affinity purified chicken anti-VP2-1 
peptide antibodies was compared to that of antibodies before affinity purification 
(non-purified) and the unbound fraction (Figure 2.27). The pooled affinity purified 
antibodies were analysed separately i.e. weeks 3-6 (A), weeks 7-11 (B) and weeks 
12-13 (C). Affinity purified antibodies from weeks 7-11 (Figure 2.27B) showed higher 
recognition of the peptide when compared with the non-purified antibodies and 
antibodies from the other weeks. All pooled affinity purified antibodies demonstrated 
higher recognition when compared to unbound, non-purified and non-immune (NI) 
antibodies although week 12 to 13 (Figure 2.27C) demonstrated a very low level of 
recognition of the peptide in an ELISA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.27 Analysis of the recognition of affinity purified chicken anti-VP2-1 
peptide antibodies by ELISA. (A) Antibodies purified from weeks 3-6 IgY. (B) Antibodies 
purified from weeks 7-11 IgY. (C) Antibodies purified from weeks 12-13 IgY.  ELISA plates 
were coated with 1 µg/mL VP2-1 peptide and probed with a dilution series of antibodies (250 
µg/mL - 0.001
 
µg/mL), followed by detection with rabbit anti-chicken IgY-HRPO conjugate 
(1:12 000) followed by ABTS/H2O2 chromogen-substrate. Each plot is the average 
absorbance reading at 405 nm of duplicate experiments. 
 
 
The affinity purified chicken anti-VP2-1 peptide antibodies were analysed to 
determine whether they could detect recombinant VP2 in an ELISA (Figure 2.28). 
The high molecular mass proteins expressed in yeast and purified using MEC 
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(Figure 2.19) which were believed to be VP2 multimers were used in the ELISA. 
Purified high molecular mass proteins (1 µg/mL) was used to coat ELISA plates and 
incubated with affinity purified chicken anti-VP2 peptide antibodies. The anti-VP2 
peptide antibodies successfully detected the high molecular mass proteins when 
compared to the non-immune (NI) control further supporting the hypothesis that 
these proteins were VP2 multimers and was as a result used in subsequent 
experiments. The weeks 7-11 antibodies showed the best recognition compared to 
antibodies from the non-immune (NI) control, weeks 3-6 and weeks 12-13 
antibodies. The results suggest that the peptides were localised in an accessible 
position on the protein, as shown by the Cn3D™ - derived structure (Figure 2.22). 
 
 
 
 
 
 
 
 
 
 
Figure 2.28 Detection of recombinant VP2 by affinity purified chicken anti-VP2-1 
peptide antibodies in an ELISA. A coating concentration of 1 µg/mL recombinant VP2 was 
used and probed with a dilution series of affinity purified chicken anti-VP2 peptide antibodies 
(250 µg/mL – 0.001
 
µg/mL) before detection with rabbit anti-chicken IgY-HRPO conjugate 
(1:12 000) followed by ABTS/H2O2 chromogen-substrate. Each plot is the average 
absorbance reading at 405 nm of duplicate experiments. 
 
 
2.4.6 Production and purification of chicken anti-VP2 antibodies 
Antibodies produced by two chickens immunised with purified VP2 expressed in 
E. coli were pooled according to the weeks of production after the first immunisation 
and antibody production monitored over a 12 week period (Figure 2.29).  Production 
of antibodies began peaking after the second booster immunisation at week 4 and 
continued to increase up to week 6. A slight decrease in production was noted after 
week 6, but remained high and constant up to week 12. 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.29 ELISA plot demonstrating chicken anti-VP2 antibody production over a 
12 week period. Chickens were immunised with purified VP2 expressed in E. coli and the 
antibody production monitored. ELISA plates were coated with 1 µg/mL VP2 and probed with 
100 µg chicken anti-VP2 antibodies followed by detection with rabbit anti-chicken IgY-HRPO 
(1:12 000) and ABTS/H2O2 chromogen-substrate. Each plot is the average absorbance 
reading at 405 nm of duplicate experiments. 
 
 
The chicken anti-VP2 antibodies isolated from each week after immunisation were 
further analysed for antibody titre by ELISA (Figure 2.30). Antibodies isolated from 
every other week from week 3 to week 12 were analysed along with a pre-immune 
antibody as a negative control. A high antibody titre was observed from week 3 
which continued to increase up to week 12 which demonstrated the highest antibody 
titre. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.30 Analysis of chicken anti-VP2 antibody titres over a 12 week period by 
ELISA. Antibodies isolated from weeks 3 to 12 were analysed for levels of titre. ELISA plates 
were coated with 1 µg/mL recombinant VP2 and probed with a dilution series of antibodies 
(250 µg/mL – 0.001
 
µg/mL) from alternate weeks followed by detection with rabbit anti-
chicken IgY-HRPO and ABTS/H2O2 chromogen-substrate. Each datapoint is the average 
absorbance reading at 405 nm of duplicate experiments. 
-log [IgY] (mL) 
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Isolated antibodies were pooled into two separate groups, weeks 3 to 7 and weeks 8 
to 12, for affinity purification. Each group was affinity purified on a VP2-AminoLink® 
Plus resin prepared with purified VP2 expressed in yeast. Fractions eluted with a 
low pH buffer showed that comparable amounts of affinity purified antibody were 
obtained from the two pools; weeks 3 to 7 and 8 to 12 (Figure 2.31). 
 
 
 
 
 
 
 
 
 
Figure 2.31 Elution profiles of affinity purified chicken anti-VP2 antibodies. Isolated 
antibodies from weeks 3 to 7 and weeks 8 to 12 were affinity purified. The arrow indicates 
the point at which elution began.  
 
 
The affinity purified antibodies were analysed by indirect ELISA and compared with 
a non-immune (NI) control, unbound antibodies and non-purified antibodies to 
determine the level of recognition of the VP2 antigen (Figure 2.32). Both affinity 
purified antibody preparations demonstrated a higher level of recognition compared 
to that of the non-immune control, non-purified and unbound antibodies (Figure 
2.32A and B).The same trend was observed for purified chicken anti-VP2 antibodies 
of weeks 8 to 12 (Figure 2.32B). Antibodies were therefore successfully affinity 
purified. 
 
 
 
 
 
 
 
 
 
Figure 2.32 Analysis of the recognition of affinity purified chicken anti-VP2 
antibodies by ELISA. (A) Antibodies purified from weeks 3-7. (B) Antibodies purified from 
weeks 8-12. ELISA plates were coated with 1 µg/mL recombinant purified VP2 and probed 
with a dilution series of antibodies (200 µg/mL – 0.1
 
µg/mL) followed by detection with rabbit 
anti-chicken IgY-HRPO and ABTS/H2O2 chromogen-substrate. Each plot is the average 
absorbance reading at 405 nm of duplicate experiments. 
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Since purified VP2 expressed in P. pastoris (Figure 2.20C) would be used in a 
VOPBA to identify possible IBDV receptor(s), chicken anti-VP2 peptide and chicken 
anti-VP2 antibodies were analysed for their ability to recognise the recombinant 
protein in a western blot (Figure 2.33). The antibodies demonstrated specificity by 
not binding to proteins expressed in the non-induced lysate (lane 1). The high 
molecular mass VP2 proteins were successfully recognised by both chicken anti-
VP2 peptide (lane 2) and chicken anti-VP2 (lane 3) antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.33 Western blot analysis of recombinant VP2 with affinity purified chicken 
anti-VP2 antibodies and chicken anti-VP2 peptide antibodies. Lane M, PageRuler™ 
Prestained Protein Ladder; lane 1, non-induced control lysate and purified VP2 expressed in 
P. pastoris, detected with chicken anti-VP2 peptide antibodies (lane 2) and chicken anti-VP2 
antibodies (lane 3). Arrow indicates VP2. 
 
 
2.5 DISCUSSION 
Outer capsid protein, VP2, contains neutralising epitopes and is the receptor binding 
protein of IBDV (Yip et al., 2007). It therefore plays a vital role in IBDV entry. Viral 
entry is the first step in the virus life cycle and understanding this mechanism could 
lead to understanding the pathogenesis of the virus as well as allow the successful 
production of inhibitors or drugs which prevent entry of IBDV into host cells. Most 
viruses bind to receptors on the host cell membrane to gain entry. The receptors for 
IBDV entry have not been conclusively identified therefore the objective of the 
present study was to use potential receptor binding proteins to help identify the 
receptor(s) of IBDV. The work described in this chapter reports on the recombinant 
expression of VP2 in bacteria and yeast, purification of recombinant VP2 and 
production of antibodies against a VP2 peptide and against VP2. 
The VP2 coding region was previously cloned into a T-vector and sub-cloned into 
the pGEX-4T-1 and pET-32a expression vectors. In the current study the VP2 gene 
66 
 
was also sub-cloned into the pPIC9 yeast expression vector and all three expression 
systems used for the expression of VP2. Proteins expressed using the pGEX-4T-1 
system are expressed with an N-terminal GST tag of 26 kDa thus VP2 (47 kDa) 
would be expressed as a 73 kDa fusion protein. However, expression of VP2 using 
the pGEX-4T-1 system failed despite increasing the final IPTG concentration used 
for induction of expression. It is not clear why expression failed in this system as it 
was previously used to successfully express the IBDV VP4 protease (Vukea, 2011). 
Taking into account that exact conditions for expression vary for each fusion protein, 
further optimisation of culture conditions (cell strain, medium composition, 
temperature and IPTG concentration) failed to improve expression. It is interesting 
that even though the system expressed VP4, it was unable to express VP2. The 
VP4 protease is similar to E. coli Lon proteases (Birghan et al., 2000, Botos et al., 
2004) therefore a reason for non-expression of VP2 in the pGEX-4T-1 system could 
be codon usage bias much like that experienced in expression of Plasmodium 
proteins in E. coli (Baca and Hol, 2000). Since expression in E. coli failed using the 
pGEX-4T-1 vector, expression of VP2 was attempted with the pET-32a vector. 
 
Proteins expressed using the pET-32a vector have an N-terminal 17 kDa thioredoxin 
and histidine tag (Trx-His tag) thus would express VP2 as a fusion protein of 64 
kDa. The pET-32a vector differs from pGEX-4T-1 in that it has a T7 promoter. The 
E. coli BL21(DE3) cells transcribe T7 RNA polymerase therefore auto-induced 
expression is possible in this system (Jia et al., 2011). Both auto-induced and IPTG 
induced expression of VP2 were performed. The VP2 protein was successfully 
expressed as a 64 kDa fusion protein through auto-induction in Terrific broth as 
inclusion bodies at both 30°C and 37°C. Studies have shown that decreasing the 
expression temperature (Schein and Noteborn, 1988), co-expression with a 
chaperone (Goloubinoff et al., 1989) and fusion with a short peptide (Makrides, 
1996) could increase the solubility of a recombinant protein. Expression of VP2 with 
a Trx-His fusion tag and at lower temperatures did not increase the solubility of the 
recombinantly expressed protein. Previous studies have confirmed that the 
formation of inclusion bodies is not dependant on the characteristics of the 
expressed protein such as molecular mass, use of fusion tags or the hydrophobicity 
of the recombinant protein, but on charge average (Kane and Hartley, 1988, 
Wilkinson and Harrison, 1991). Additionally, over-expression of proteins can cause 
the formation of inclusion bodies (Gribskov and Burgess, 1983). Expression of VP2 
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as inclusion bodies posed a problem, but due to the presence of a His-tag, 
purification could still be performed under denaturing conditions using a nickel 
affinity column (QIAGEN instruction manual, 1997). Inclusion bodies were 
successfully solubilised in 8 M urea. Initially VP2 did not bind efficiently to the resin 
and some proteins were released during the washing step. In addition, VP2 also 
eluted with contaminating bacterial proteins. Therefore the protein fractions from the 
washing step were applied to a cation-exchange chromatography column using 
step-wise elution with NaCl for further purification and pure VP2 was eluted using 
0.5 M NaCl.   
 
In order to increase VP2 yields in addition to purified VP2 obtained using cation-
exchange chromatography, the study also took advantage of on-column refolding of 
the protein. A decreasing gradient wash from 8 to 0 M urea was applied to the nickel 
column allowing the bound protein to slowly refold. There are a few methods 
available to refold proteins such as direct dilution which uses refolding buffers to 
slowly dilute out denaturant, membrane controlled denaturant removal which uses 
step-wise dialysis and the chromatographic method which uses buffer exchange to 
remove denaturant (Vallejo and Rinas, 2004). On-column refolding offers several 
advantages. It is cheap, fast, easily automated and can be applied to a broad range 
of proteins (Oganesyan et al., 2005). The VP2 protein was successfully purified and 
renatured by on-column refolding as evidenced by a visible size-shift on SDS-PAGE 
of the non-reduced refolded protein when compared to the reduced refolded protein.  
 
Additionally, VP2 expression with the pET-32a system in E. coli resulted in high 
molecular mass proteins which are believed to be incorrectly folded VP2. The IBDV 
VP2 protein has been shown to spontaneously assemble into SVPs during 
expression (Garriga et al., 2006, Lee et al., 2006b, Dey et al., 2009). The expression 
systems used in the studies which report on the assembly of SVPs are pESC-URA 
containing the VP2 coding sequence (Garriga et al., 2006) and the IBDV polyprotein 
coding sequence (Dey et al., 2009) both expressed in Saccharomyces cerevisia  
and a recombinant baculovirus containing VP2 expressed in Hi-5 cells (Lee et al., 
2006b). Assembly of IBDV VP2 has not yet been reported in E. coli. Therefore in the 
present study, electro-elution was used to substantiate the hypothesis that the high 
molecular mass proteins were in fact VP2. The electro-eluted high molecular mass 
proteins were observed at the top of the gel as well as at 64 kDa, the expected size 
of the VP2 fusion protein when analysed by SDS-PAGE which supported the 
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hypothesis that the high molecular mass proteins were VP2 and explains their 
recognition by the chicken anti-VP2 antibodies. Superoxide dismutase, an enzyme 
that catalyses dismutation of superoxide (O2
-) into oxygen and hydrogen peroxide in 
humans, has been shown to aggregate into high molecular weight, biochemically 
distinct, insoluble protein complexes much like insoluble inclusion bodies (Johnston 
et al., 2000). Therefore it is possible that the high molecular mass VP2 observed is 
in fact incorrectly folded VP2 which aggregates as high molecular mass proteins. 
Therefore VP2 was successfully expressed and purified using the pET-32a E. coli 
expression system, yielding sufficient amounts of protein to immunise chickens for 
the production of polyclonal antibodies. Although VP2 expressed well in the pET-
32a system, it was obvious that purification of the protein expressed in inclusion 
bodies posed a problem. This was evident by the low yield of purified protein. 
Therefore an alternative expression system was explored in order to obtain greater 
yields of purified protein which could be used to couple to an affinity matrix for the 
affinity purification of chicken anti-VP2 antibodies and for the use in a VOPBA 
(Chapter 3). 
 
Since previous studies on VP2 have used eukaryotic expression systems, the 
present study also explored expressing VP2 in a yeast expression host, P. pastoris, 
in an effort to obtain a higher yield of purified VP2. The P. pastoris expression 
system allows efficient production of secreted proteins (Wu et al., 2005) and 
provides the advantage of post-translational modification such as glycosylation, 
proteolytic processing, folding and disulfide bond formation (Aloulou et al., 2006). 
The VP2 protein was successfully expressed as a 47 kDa protein as expected and 
as high molecular mass proteins in the P. pastoris system as confirmed by western 
blotting using chicken anti-VP2 antibodies. The VP2 coding sequence has been 
previously cloned into the P. pastoris system with success using pHILD2 and 
pHILS1 (Pitcovski et al., 2003), pPICZαA (Wu et al., 2005) and pCR 2.1 (Villegas et 
al., 2008). In the present study the VP2 coding sequence was cloned into the pPIC9 
vector for expression in GS115 cells. Previous studies on the expression of VP2 in 
yeast did not report the expression of high molecular mass proteins (Pitcovski et al., 
2003, Wu et al., 2005, Villegas et al., 2008). However, a western blot using anti-
IBDV monoclonal antibody detected a 52 kDa recombinant VP2 and proteins greater 
in size than 75 kDa situated at the top of the gel in the study conducted by Villegas 
et al. (2008) which could be high molecular mass form of VP2. In addition, the high 
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molecular mass proteins in the current study were sufficiently detected using anti-
VP2 peptide antibodies in an ELISA and therefore confirmed to be VP2. 
 
The VP2 expressed in yeast was initially concentrated and purified by the TPP 
method developed by Pike and Dennison (1989). Three phase partitioning 
successfully concentrated the yeast expressed supernatant, but failed to remove the 
contaminating proteins, thus the concentrated sample was further purified using 
molecular exclusion chromatography. This method separated the high molecular 
mass proteins from a lower molecular mass fraction containing the 47 kDa VP2 and 
other contaminating proteins, but was not successful separating the latter. Since the 
high molecular mass proteins were confirmed to be VP2, this fraction was used for 
subsequent experiments. Following successful expression of VP2 in P. pastoris and 
purification to homogeneity, the VP2 was used to prepare an affinity column to purify 
chicken anti-VP2 antibodies. Chickens were deemed to be the best experimental 
animal to produce antibodies for a number of reasons. The antibody extraction 
method is fairly simple and straight forward and does not require bleeding to obtain 
the antibodies since they are packaged into the eggs (Goldring and Coetzer, 2003). 
In addition the quantity of antibodies isolated from a single egg yolk is comparable to 
antibodies isolated from bleeding a rabbit every 2 weeks (Gee et al., 2003). 
Recombinant VP2 expressed in P. pastoris was coupled to Aminolink® coupling 
resin and used to successfully affinity purify chicken anti-VP2 antibodies as 
evidenced by improved recognition of VP2 in an ELISA compared to IgY before 
affinity purification and non-immune antibodies.  
 
Peptides were also selected from the VP2 amino acid sequence, coupled to a 
carrier protein and used to raise polyclonal anti-peptide antibodies in chickens. The 
idea was to observe whether anti-peptide antibodies could sufficiently recognise 
recombinantly expressed VP2 and whether the level of recognition would be greater 
for chicken anti-VP2 peptide than chicken anti-VP2 antibodies. Therefore two 
peptides, VP2-1 and VP2-2, which displayed high levels of hydrophilicity according 
to the Predict7™ epitope prediction programme (Cármenes et al., 1989), were 
selected from the VP2 amino acid sequence. Even though both peptides were 
localised on the surface of the VP2 protein, higher antibody titres were observed for 
the chicken anti-VP2-1 peptide antibodies. Since only a small amount of anti-VP2-2 
peptide antibodies were produced they were not affinity purified, but retained for 
possible future use. The chicken anti-VP2-1 peptide antibodies were successfully 
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affinity purified as observed by the high recognition of purified antibodies to VP2-1 
peptide when compared to non-immune and non-purified antibodies in an indirect 
ELISA. Additionally, the anti-VP2 peptide antibodies recognised VP2 expressed in 
P. pastoris in a western blot and ELISA. Antibodies were also successfully produced 
against VP2 which supports the notion that VP2 is highly immunogenic as it is the 
primary host-protective immunogen and therefore the primary target for vaccine 
development (Chen et al., 2005). The recombinant VP2 appears to maintain the 
immunogenic properties of the native protein.  
 
In this study, VP2 was successfully expressed and purified in both E. coli and P. 
pastoris expression systems. The VP2 protein expressed as a 64 kDa fusion protein 
in the E. coli pET-32a system and as a 47 kDa in the pPIC9 yeast expression 
system. High molecular weight proteins were also observed in both expression 
systems. Expression in P. pastoris was favoured over E. coli, firstly because VP2 
expressed as a soluble protein as opposed to inclusion bodies in E. coli. Secondly 
the yield of purified VP2 was greater in P. pastoris. VP2 expressed in E. coli was 
used to raise polyclonal antibodies in chickens while VP2 expressed in P. pastoris 
was used to generate an affinity column for the successful affinity purification of 
chicken anti-VP2 antibodies. Peptides designed from the VP2 amino acid sequence 
was used to produce anti-VP2 peptide antibodies in chickens. Purified VP2, chicken 
anti-VP2 and chicken anti-VP2 peptide antibodies will be used for the identification 
of possible IBDV receptor proteins as described in Chapter 3. 
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CHAPTER 3 
IDENTIFYING POSSIBLE IBDV RECEPTOR(S) USING VIRUS 
OVERLAY PROTEIN-BINDING ASSAYS AND AFFINITY 
CHROMATOGRAPHY 
 
 
3.1 INTRODUCTION 
Infectious bursal disease virus remains one of the most economically important 
diseases in the poultry industry and although there are vaccines available they are 
often compromised by the presence of maternal antibodies (Corley and Giambrone, 
2002) and the continuous emergence of new virulent IBDV strains (Cao et al., 
1998b). There remains a need to explore other strategies to control the disease. 
One of the strategies that has proven successful is developing novel antiviral agents 
which target the stages or processes that are crucial to the life cycle of the virus, 
such as virus entry (Sharma et al., 2000, Yuan et al., 2012). Drugs or inhibitors 
against viral entry, targeting either the viral receptor binding protein or receptor(s) on 
the host cells, have been successfully developed and have been shown to prevent 
viral entry such as Enfuvirtide used for the clinical treatment of HIV (Wilen et al., 
2012). Enfuvirtide is a short peptide resembling the carboxy-terminal helical region 
of gp41, a subunit of the HIV envelope which competitively binds target molecules. 
Studies of the antiviral agents in patients show a significant improvement in 
antiretroviral activity (Lalezari et al., 2003, Hardy and Skolnik, 2004). It is therefore 
important to identify both the receptor binding protein on viral capsids or membranes 
and the receptor(s) of the host cells. The outer capsid protein VP2, is the receptor 
binding protein of IBDV (Yip et al., 2007); however, the receptor(s) on the bursal 
cells of the bursa of Fabricius have not yet been conclusively identified. 
 
There are several biochemical methods used to identify cellular receptors, some of 
which include the virus overlay protein-binding assay (VOPBA), affinity 
chromatography and the use of anti-receptor antibodies (Smith and Helenius, 2004). 
The VOPBA is similar to western blotting in that plasma membranes are separated 
by SDS-PAGE and transferred to nitrocellulose or PVDF membranes. 
Electrophoretically transferred proteins are incubated with prepared virus and 
antivirus antibodies are used to detect any proteins which the virus specifically binds 
to. The alpha-dystroglycan receptor for Lassa fever virus (Cao et al., 1998a), 
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angiotensin-converting enzyme 2 receptor for SARS coronavirus (Li et al., 2003) 
and HSP70 and STAT-2 proteins used by the chikungunya virus to establish 
infection of mammalian cells (Paingankar and Arankalle, 2014) have been identified 
using the VOPBA method. In affinity chromatography, the virus or receptor binding 
protein is coupled to an affinity matrix and used to isolate all binding proteins which 
may represent the receptor proteins. Encephalomyocarditis virus bound to an affinity 
matrix was used to successfully isolate candidate receptor(s) on human nucleated 
cells (Jin et al., 1994) and membrane cofactor protein was identified as the 
Adenovirus receptor by use of affinity chromatography (Trauger et al., 2004). Anti-
receptor antibodies are also often used to immunopurify receptors for example a 
110 kDa glycoprotein receptor for mouse hepatitis virus (Williams et al., 1990) and 
the Human membrane cofactor protein (CD46) used by the measles virus (Naniche 
et al., 1993) were purified using monoclonal antibodies. 
 
Although the IBDV receptor(s) has not been conclusively identified, several different 
membrane proteins have been shown to interact with IBDV. The virus has been 
shown to target surface IgM positive lymphocytes (Hirai and Calnek, 1979) which 
led researchers to believe that IgM was the IBDV receptor although this was later 
shown to be incorrect (Ogawa et al., 1998). Nieper and Muller (1996) performed 
saturation and competition experiments using radiolabelled IBDV of serotype I and II 
and chicken embryo fibroblast (CEF) cells which are susceptible to both serotypes. 
The study demonstrated that CEF cells have receptor proteins which are specific to 
both serotypes as well as specific receptors for each serotype (Nieper and Muller, 
1996). Furthermore, VOPBA results showed two proteins of 40 and 46 kDa on the 
surface of CEF cells which specifically bound to both serotypes of IBDV (Nieper and 
Muller, 1996). In a study conducted by Ogawa et al. (1998), IBDV binding to B-cells 
was demonstrated, however when treated with proteases and N-glycosylation 
inhibitors, binding was inhibited. These results suggest that the receptor is a protein 
which could be N-glycosylated (Ogawa et al., 1998).  
 
Later, VOPBA experiments were performed using plasma membranes of LSCC-BK3 
cells from a chicken B lymphoblastoid cell line which is also susceptible to IBDV 
infection (Setiyono et al., 2001). Three proteins of 70, 82 and 110 kDa were shown 
to specifically bind to IBDV (Setiyono et al., 2001). Lin et al. (2007) were the first 
study to identify a protein which forms part of the receptor and is essential for IBDV 
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entry. Instead of IBDV particles, the study used subviral particles (SVPs) formed by 
VP2 (Coulibaly et al., 2005, Lin et al., 2007). The SVPs were cross-linked to 
immobilised Ni2+ ions on an affinity matrix and used to affinity purify binding proteins 
of DF-1 cells. Purified protein was identified as chicken heat shock protein 90 
(cHsp90) by mass spectrometry (Lin et al., 2007) and VOPBA using IBDV viral 
particles further confirmed the result. Furthermore the infection of DF-1 cells by 
IBDV was also shown to be inhibited by cHsp90 and by anti-cHsp90 antibodies. 
 
The objective of this part of the present study was to identify possible IBDV 
receptor(s) that are present on the bursal membranes using the receptor binding 
protein VP2. The approach was to detect any bursal membrane proteins which 
interact with IBDV using a conventional and modified VOPBA and purifying possible 
IBDV binding proteins using affinity chromatography on a VP2-coupled affinity 
matrix. Plasma membrane proteins were therefore isolated from the bursae, 
separated by SDS-PAGE and transferred onto nitrocellulose. For the conventional 
VOPBA, isolated IBDV was incubated with the nitrocellulose containing transferred 
plasma membrane proteins. Any proteins which interacted with IBDV were detected 
using either chicken anti-VP2 or chicken anti-VP2 peptide antibodies. The modified 
VOPBA incorporated VP2, in place of IBDV, to determine if the interactions would 
be comparable. The IBDV binding proteins of the plasma membrane were also 
purified on a VP2-coupled affinity matrix and further analysed by mass 
spectrometry.  
 
 
3.2 MATERIALS 
The IBDV infected bursae were obtained from Allerton Regional Veterinary 
laboratory, Pietermaritzburg, South Africa and non-infected bursae from Ukulinga 
research and training farm, University of KwaZulu-Natal, Pietermaritzburg, South 
Africa. Vero cells were available as glycerol stocks. Minimum essential medium 
(MEM), HEPES and ProteoPrep® membrane extraction kit were purchased from 
Sigma-Aldrich-Fluka (Steinheim, Germany). Heat inactivated foetal calf serum (FCS) 
was purchased from Gibco (Paisley, UK). Sterile membrane filters (0.2 μm and 0.45 
µm) were purchased from Pall (Ann Arbor, USA) and culture flasks (75 cm2) were 
obtained from Corning (New York, USA). PageRuler™ plus prestained protein 
ladder was purchased from Fermentas (Vilinius, Lithuania). 
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3.3 METHODS 
3.3.1 Preparation of plasma membranes from the bursa of Fabricius 
Plasma membranes from the bursae were prepared according to Nieper and Muller 
(1998). Briefly, fresh bursae were suspended in washing buffer (25 mM HEPES, 
154 mM NaCl, 0.5 mM MgCl2, pH 7.4) and excised carefully with scissors. The cells 
were washed three times in washing buffer before resuspending in three-fold (w/v) 
excess of ice-cold homogenisation buffer (25 mM HEPES, 30 mM NaCl, 0.5 mM 
MgCl2, 1 mM DTT, 1 mM PMSF, 1 µM pepstatin A, pH 8.0) and incubated on ice for 
10 min. The resuspended cells were homogenised in a Potter S homogeniser by 30-
40 strokes and restoration buffer (25 mM HEPES, 600 mM NaCl, 0.5 mM MgCl2, pH 
8.0) added immediately to a final concentration of 154 mM NaCl to restore isotonic 
conditions. EDTA was added to the homogenate to a final concentration of 1 mM 
and the homogenate centrifuged (5 000 x g, 10 min, 4°C).  The pellet was discarded 
and two parts of the supernatant were layered over one part of a 25% (w/v) sucrose 
cushion made up in homogenisation buffer before ultracentrifugation (100 000 x g, 1 
h, 4°C). The plasma membranes were collected at the interface which was visible as 
a white band and diluted in washing buffer before sedimentation by 
ultracentrifugation (100 000 x g, 30 min, 4°C). The white band at the interface was 
collected and resuspended in washing buffer. Before SDS-PAGE analysis the 
resuspended isolate was concentrated by adding 10 µL of 5% (w/v) SDS and 10 µL 
3 M KCl to 100 µL resuspended isolate in a microfuge tube and mixed together by 
inverting. The mixture was centrifuged (12 000 x g, 2 min, RT), the supernatant 
discarded and the precipitate resuspended in 10 µL of gel buffer (0.5 M Tris-HCl, pH 
6.8) and 10 µL of reducing treatment buffer [0.125 M Tris-HCl, 4% (w/v) SDS, 20% 
(v/v) glycerol, 10% (v/v) 2-mercaptoethanol, pH 6.8]. 
 
Plasma membranes were also prepared using the ProteoPrep® membrane 
extraction kit (Sigma-Aldrich-Fluka, Steinheim, Germany) according to the 
manufacturer’s instructions with minor modifications. Briefly, excised fresh bursae (1 
g) was suspended in ice cold Soluble cytoplasmic and loosely-bound membrane 
protein extraction reagent (8 mL) (Sigma-Aldrich-Fluka, Germany) before disruption 
by homogenisation using a Potter S homogeniser by 30-40 strokes. Ice cold Soluble 
cytoplasmic and loosely-bound membrane protein extraction reagent (50 mL) was 
added to the homogenate and slowly stirred on ice for 1 h before being subjected to 
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ultracentrifugation (115 000 x g, 1 h, 4°C) to pellet membranes and membrane 
proteins. The supernatant was discarded and the membrane pellet was thoroughly 
resuspended and washed twice in 2 mL milliQ water with centrifugation between 
washes (20 000 x g, 20 min, 4°C). Thereafter the pellet was resuspended in Protein 
extraction reagent type 4 (2 mL) (Sigma-Aldrich-Fluka, Germany) and sonicated on 
ice (4 x 15 s pulses) before centrifugation (14 000 x g, 45 min, 15 °C) to pellet cell 
debris. The supernatant containing plasma membranes was retained and the 
concentration determined, before analysis by SDS-PAGE (Section 2.3.5.2). 
 
 
3.3.2 IBDV isolation and cell culture 
3.3.2.1 Isolation of IBDV from infected bursae samples 
The IBDV virus particles were isolated from infected bursae according to 
Fernandez-Arias et al. (1998) with some modifications. Briefly, homogenisation 
buffer (0.02 M Tris-HCl, pH 7.8) was added in an equal volume to excised infected 
bursae and homogenised using a Potter S homogeniser. The cell debris was 
removed with centrifugation (17 000 x g, 15 min, 4°C) and one part supernatant was 
layered on two parts of 40% (w/v) sucrose in homogenisation buffer and 
ultracentrifuged (86 000 x g, 2.5 h, 4°C). The supernatant was discarded and the 
pellet was thoroughly resuspended in homogenisation buffer. The resuspended 
pellet was layered over half its volume of 1.37 g/cm3 CsCl solution and 
ultracentrifuged (86 000 x g, 6 h, 4°C). The virus band which was observed towards 
the top of the gradient was removed by aspiration using a Pasteur pipette and 
resuspended in homogenisation buffer before dialysing in buffer (0.01 M Tris-HCl 
buffer, pH 7.8) overnight to remove CsCl. The dialysed sample was layered again 
over half its volume of a 1.27 g/cm3 CsCl solution and ultracentrifuged (86 000 x g, 6 
h, 4°C). The band containing virus was collected and resuspended in 
homogenisation buffer and analysed by SDS-PAGE (Section 2.3.5.2). 
 
 
3.3.2.2 Preparation of Vero cell monolayers 
The preparation of Vero cell monolayers were carried out according to Hussain and 
Rasool (2005) with a few modifications. A vial of cryogenic Vero cells (2 mL) at its 
twentieth passage were removed from liquid nitrogen and thawed. The cells were 
transferred into a 15 mL tube and the volume made up to 6 mL with complete MEM 
[MEM base powder, 26 mM NaHCO3, 10% (w/v) FCS, 1% (w/v) penicillin-
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streptavidin]. The Vero cell suspension was split (3 x 2mL) and transferred to culture 
flasks (75 cm2). To each flask complete MEM (10 mL) was added and incubated at 
37°C with 5% CO2. The flasks were examined twice daily under an inverted 
microscope (Olympus CK40, Japan) for the formation of a 100% confluent 
monolayer (48 h). The 100% confluent monolayer was subcultured by removing 
spent medium and washing twice with pre-warmed PBS (3 mL). Cells were 
trypsinised and brought into suspension using pre-warmed 0.25% trysin-EDTA (3 
mL) and incubated for 30 min at 37°C with 5% CO2. Cells were lifted by gently 
hitting the side of the flasks. Complete MEM (6 mL) was added to each flask before 
splitting cells three way and transferring to new culture flasks (75 cm2). The volume 
was made up to 6 mL with complete MEM before incubation at 37°C with 5% CO2. 
The cells were examined twice daily under an inverted microscope for the formation 
of a 90% confluent monolayer. 
 
 
3.3.2.3 Infection of Vero cell monolayers with IBDV and harvesting of IBDV 
Infection of Vero cell monolayers was carried out according to Ahasan et al. (2002) 
with some modifications. Isolated IBDV virus (Section 3.3.2.1) was used to infect the 
90% confluent monolayers. Briefly, the spent medium was removed and cell 
monolayers were washed twice with prewarmed PBS (3 mL). To each flask 1 mL 
IBDV inoculum was added by using a 0.2 µm pore filter steriliser. The inoculum was 
spread evenly over the Vero cell monolayer and incubated at 37°C for 1 h with 
intermittent rotation to ensure absorption. Two culture flasks were kept as non-
induced controls. After allowing virus absorption, complete MEM (5 mL) was added 
to each culture flask and incubated at 37°C with 5% CO2. Flasks were examined 
twice daily under an inverted microscope for cytopathic effects (96 h). The virus was 
harvested by three freeze-thaw cycles according to Peilin et al. (1997). Medium 
containing virus was transferred to 10 mL tubes, frozen overnight at -20°C and 
thawed at RT. This freeze-thaw process was repeated three times before the virus 
suspension was centrifuged (4 420 x g, 5 min, 4°C) to pellet cell debris and the 
supernatant was stored at -80°C till further use. 
 
 
3.3.3 VOPBA to identify possible receptor proteins to which IBDV binds 
The VOPBA was carried out according to Karger and Mettenleiter (1996) with some 
modifications. Briefly, isolated plasma membrane proteins (25 µg) were separated 
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on a 10% reducing SDS-PAGE (Section 2.3.5.2) and transferred electrophoretically 
to nitrocellulose at 30 V in blotting buffer [20 mM Tris-HCl, 192 mM glycine, 20% 
(v/v) methanol, 1% (w/v) SDS] overnight. The nonspecific sites on the membrane 
were blocked with 5% (w/v) non-fat milk in TBS (20 mM Tris, 200 mM NaCI, pH 7.4) 
for 1 h. Thereafter the membrane was washed with TBS (3 x 5 min) and incubated 
for 2 h with either purified IBDV (1:50, according to a previous study conducted in 
the laboratory) or purified VP2 (50 µg) made up in 0.5% (w/v) BSA-TBS. Following 
incubation, the membrane was washed in TBS (3 x 5 min) and incubated with either 
chicken anti-VP2 or chicken anti-VP2 peptide antibodies (100 µg) made up in 0.5% 
(w/v) BSA-TBS for 2 h. The membrane was washed in TBS (3 x 5 min) and 
incubated in rabbit anti-chicken IgY secondary antibody conjugated to horse radish 
peroxidase (HRPO) for 1 h. The membrane was washed with TBS (3 x 5 min) before 
immersing in chromogen/substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.1% 
(v/v) methanol, 0.0015% (v/v) H2O2 in TBS), allowed to develop in the dark (3-5 min) 
until bands were clearly evident against a lightly stained background and thereafter 
transferred to distilled water. 
 
 
3.3.4 Affinity purification of IBDV receptor proteins 
A VP2 coupled AminoLink® column (1 mL) (Section 2.3.4.5) was used to affinity 
purify possible IBDV receptor proteins. A 1 M NaOH solution was used to clean and 
regenerate the column before equilibrating with 20 column volumes of washing 
buffer [100 mM sodium phosphate buffer, pH 6.5, 0.02% (w/v) NaN3] at a flow rate 
of 10 mL/h. Isolated plasma membranes (Section 3.3.1) were thawed and filter 
sterilised with a 0.45 µm pore size filter before circulating overnight on the affinity 
column at 4°C. The unbound fraction was collected and the affinity column was 
washed with 10 column volumes of washing buffer before applying elution buffer 
(100 mM glycine-HCl buffer, pH 2.8). Fractions were collected (0.5 mL) and A280 
readings measured. Fractions containing protein were pooled and analysed by 10% 
reducing SDS-PAGE and stained with Coomassie blue R-250 (Section 2.3.5.2). 
 
 
3.3.5 Tandem Mass Spectrometry 
Affinity purified proteins were prepared for mass spectrometry by separating the 
sample by SDS-PAGE and staining with Coomassie blue R-250 (Section 2.3.5.2). 
The protein bands were excised and MS analysis conducted (CSIR BioSciences, 
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Pretoria, South Africa). Protein bands were in-gel trypsin digested according to 
Shevchenko et al. (2007). Briefly, protein bands were excised from the gel and 
destained in 100 mM NH4HCO3/acetonitrile (1:1 v/v) for 30 min followed by 
incubation at RT with acetonitrile until gel pieces became white. Protein digestion 
was carried out in a negligible volume (~50 µL, depending on size of gel piece) of 10 
ng/µL trypsin overnight at 37°C. The digested sample was resuspended in 35 µL 2% 
acetonitrile/0.2% formic acid before analysis on a Dionex Ultimate 3000 ELITE mass 
spectrometer (Thermo Scientific, Roskilde, Denmark). The ProteinPilot™ v4.0.8085 
software which uses the Paragon™ Algorithm was used for comparison of the 
obtained MS/MS spectra with protein sequences in a Uniswiss 2011 database. 
Proteins with threshold above ≥ 99.9% confidence were reported.  
 
 
3.4 RESULTS 
3.4.1 Analysis of plasma membrane isolation 
Plasma membrane proteins were isolated from the bursa of Fabricius of healthy 
chickens using two methods. The first was a method described by Nieper and Muller 
(1998) and the second, a ProteoPrep® membrane extraction kit based on protocols 
described by Molloy et al. (1998) and Herbert et al. (1998). Reducing SDS-PAGE 
was used to analyse the isolated plasma membranes (Figure 3.1). A low yield was 
obtained with the conventional method described by Nieper and Muller (1998), 
although faint protein bands of about 40, 43, 60 and 90 kDa were observed after 
concentrating the plasma membrane isolate (Figure 3.1, lane 1). A greater yield was 
obtained using the ProteoPrep® membrane extraction kit and further concentrating 
steps were not required before analysis by SDS-PAGE. Prominent protein bands of 
approximately 40, 43, 70, 90 kDa and a high molecular weight protein were 
observed (Figure 3.1, lane 2). Three prominent protein bands of 40, 43 kDa and a 
high molecular weight protein were observed by Nieper and Muller (1998)  which 
correlates well with results obtained using the extraction kit. 
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Figure 3.1 Analysis of isolated plasma membrane proteins separated by 10% reducing 
SDS-PAGE stained with Coomassie Blue R-250. Lane M, PageRuler plus prestained 
protein ladder; lane 1, membranes isolated using a conventional method and lane 2 
membranes isolated using an extraction kit. Arrows indicate major proteins. 
 
 
3.4.2 The isolation of IBDV from infected bursae and the infection of Vero 
cells 
Infectious bursal disease virus was isolated from IBDV infected bursae and 
analysed by reducing SDS-PAGE (Figure 3.2). The virus comprises two structural 
proteins, VP2 (47 kDa) and VP3 (32 kDa), which together form the capsid and make 
up 80-90% of the total protein of birnaviruses (Dobos, 1996). Three non-structural 
proteins of IBDV include VP1 (90 kDa), VP4 (28 kDa) and VP5 (17 kDa). The 
structural proteins, VP2 and VP3 were observed at an expected size of 47 and 32 
kDa, respectively (lane 1). A protein band at 28 kDa (likely to be VP4) was also 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Analysis of isolated IBDV by 10% reducing SDS-PAGE stained with 
Coomassie Blue R-250. Lane M, PageRuler Plus Prestained Protein Ladder; lane 1, 
isolated IBDV. Arrows indicate protein bands that correspond to structural proteins VP2 and 
VP3 and the VP4 protease. 
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Isolated IBDV was propagated in Vero cells (Figure 3.3). The morphology of the 
Vero cells before infection can be described as fibroblast-like (Figure 3.3A). 
Following infection, cytopathic effects were observed 96 h post-infection (Figure 
3.3B). The cells displayed a change from a fibroblast-like morphology to a more 
rounded morphology with visible aggregates. 
 
 
 
 
 
 
 
 
 
Figure 3.3 Photo images of Vero cells taken using an inverted microscope. (A) A 90% 
confluent monolayer of Vero cells grown in complete MEM growth medium. (B) Cytopathic 
effects of IBDV on Vero cell monolayer 96 h post-infection (magnification 100x). 
 
 
3.4.3 Identifying possible IBDV receptor proteins 
3.4.3.1 IBDV binding proteins detected using VOPBA experiments 
A VOPBA was used to identify possible receptor(s) or IBDV binding proteins on the 
plasma membranes isolated from the bursae using either chicken anti-VP2 or 
chicken anti-VP2 peptide antibodies (Figure 3.4). Before the VOPBA was 
performed, VP2, IBDV, chicken anti-VP2 and chicken anti-VP2 peptide antibody 
concentrations were optimised by methodically varying one parameter at a time. In 
the VOPBA experiments, VP2 bound to two proteins of 70 and 32 kDa (Figure 3.4A, 
lane 2) which was recognised by chicken anti-VP2 antibodies. No detection was 
observed using chicken anti-VP2 peptide antibodies (Figure 3.4B, lane 2). A 32 kDa 
protein was observed binding to IBDV as recognised by chicken anti-VP2 antibodies 
(Figure 3.4C, lane 2) while no detection was observed using chicken anti-VP2 
peptide antibodies (Figure 3.4D, lane 2). It is expected that the use of chicken anti-
VP2 antibodies would identify more proteins than the chicken anti-VP2 peptide 
antibodies as the anti-peptide antibodies are targeted to a specific region on the 
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protein in comparison to anti-protein antibodies which recognise many epitopes on 
the protein. 
 
The IBDV particles cultured in Vero cells (Figure 3.4, lane 3) and recombinant VP2 
(Figure 3.4, lane 5) were also separated by SDS-PAGE to serve as positive controls 
for the binding of the primary antibodies. Both chicken anti-VP2 and chicken anti-
VP2 peptide antibodies recognised the recombinant VP2 at its expected size of 45 
kDa and the high molecular mass proteins (Figure 3.4, lane 5), but was unable to 
detect native VP2 in the isolated virus (Figure 3.4, lane 3). Since IBDV was able to 
infect Vero cells, the cells were also separated by SDS-PAGE to determine if they 
would yield comparable results to the bursal membrane. Neither chicken anti-VP2 
nor chicken anti-VP2 peptide antibodies detected the proteins on Vero cells 
suggesting that neither VP2 nor IBDV bound to any proteins on Vero cells (Figure 
3.4, lane 4). 
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Figure 3.4 VOPBA analysis of possible IBDV receptor proteins. (A) VOPBA probed with 
50 µg/mL VP2, 100 µg/mL chicken anti-VP2 antibodies and 1:12000 rabbit anti-chicken 
antibodies. (B) VOPBA probed with 50 µg/mL VP2, 100 µg/mL chicken anti-VP2 peptide 
antibodies and 1:12000 rabbit anti-chicken antibodies. (C) VOPBA probed with 1:50 IBDV, 
100 µg/mL chicken anti-VP2 antibodies and 1:12000 rabbit anti-chicken antibodies. (D)  
VOPBA probed with 1:50 IBDV, 100 µg/mL chicken anti-VP2 peptide antibodies and 1:12000 
rabbit anti-chicken antibodies. Lane M, PageRuler plus prestained protein ladder; lanes 1 
and 2, isolated plasma membrane proteins; lane 3, isolated IBDV; lane 4, Vero cells and 
lane 5, VP2. Arrows indicate proteins which were detected. 
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3.4.3.2 Affinity purification of possible IBDV receptor proteins 
Affinity chromatography was used for the isolation of possible IBDV receptor(s) from 
bursae and the proteins were analysed by reducing SDS-PAGE (Figure 3.5). A VP2 
coupled AminoLink® column was used to isolate the receptor(s) by passing isolated 
plasma membranes of the bursae (lane 1) through the column. During the affinity 
purification, non-specific proteins were collected in the unbound fraction (lane 2) and 
the column was washed to remove any additional non-specific binding proteins (lane 
3). Finally, all proteins which strongly bound to VP2 were eluted using a low pH 
buffer (lanes 4 and 5). Four prominent VP2 binding proteins were observed with 
molecular masses of approximately 70, 60, 45 and 32 kDa. These protein molecular 
masses correlate with the sizes that have been reported in previous studies. A 
VOPBA conducted by Setiyono et al. (2001) and Nieper and Muller (1996) reported 
on IBDV specifically binding to proteins of 70 kDa and 46 kDa respectively, while a 
study previously conducted in our laboratory reported on a 32 kDa protein as a 
predominant protein observed binding to IBDV (Edwards, 2000). Reports could not 
be established which identify IBDV interacting with a 60 kDa protein. 
 
 
 
 
 
 
 
 
 
Figure 3.5 Analysis of possible IBDV receptor proteins eluted from a VP2 affinity 
column. Proteins were separated by 10% reducing SDS-PAGE and stained with Coomassie 
Blue R-250. Lane M, molecular weight marker; lane 1, isolated plasma membrane proteins, 
lane 2, unbound fraction; lane 3, wash fraction and lanes 4 and 5, elution fractions. Arrows 
indicate the four eluted proteins which were further analysed. 
 
3.4.3.3 Mass spectrometry of affinity purified proteins 
Tandem mass spectrometry was performed to identify the affinity purified proteins. 
Mass spectrometry analysis identified one protein with common peptides to the 70 
kDa protein, two proteins with common peptides to the 60 kDa protein, two proteins 
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with common peptides to the 45 kDa protein and three proteins with common 
peptides to the 32 kDa protein (Table 3.1). All peptides were identified with at least 
95% confidence and the proteins identified demonstrated identity of more than two 
peptides to the affinity purified proteins. Bacterial contamination was ruled out. 
Peptides of the immunoglobulin gamma chain showed identity to peptides of all four 
of the affinity purified proteins which suggests the presence of an antibody. The 60 
and 45 kDa proteins also contain peptides which show identity to peptides of the 60 
kDa chaperonin of Pseudomonas fluorescens and elongation factor Tu of Yersinia 
pestis (43 kDa) respectively which is involved in peptide bond synthesis. The 32 kDa 
protein contains peptides which show identity to peptides of the outer major protein 
of Serratia marcescens (37 kDa) and peptides of the Ig lambda chain of Gallus 
gallus. All homologous peptides are shown in the Appendix. 
 
 
Table 3.1 Summary of MS analysis of possible affinity purified IBDV receptor 
proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*peptides have been identified with at least 95% confidence 
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3.5 DISCUSSION 
The identification of virus receptors is crucial to the understanding of virus 
pathogenesis and their mechanism of entry into susceptible cells. Even though the 
IBDV receptor(s) has not been identified, VP2 has been shown to be the receptor 
binding protein (Yip et al., 2007). The present study was aimed at identifying the 
proteins which bind to IBDV and VP2 and may therefore represent the IBDV 
receptor(s). In the previous chapter, VP2 was recombinantly expressed and purified. 
In work described in the current chapter, IBDV was isolated from infected bursal 
tissue and the isolated virus was allowed to propagate in Vero cells and purified. 
Purified IBDV or VP2 was used in a virus overlay protein-binding assay (VOPBA) to 
identify possible receptor proteins. In addition VP2 binding proteins of the bursae 
were affinity purified and analysed by mass spectrometry. 
The bursa of Fabricius is the target organ for IBDV, therefore the first part of the 
current study required the isolation of plasma membrane proteins from the bursae to 
identify proteins specifically binding to VP2 or IBDV. Two methods were used to 
isolate the membranes. The first method is a protocol described by Nieper and 
Muller (1998) which uses high speed centrifugation washes and the second method 
used a ProteoPrep® membrane extraction kit (Sigma-Aldrich-Fluka, Steinheim, 
Germany) based on protocols described by Molloy et al. (1998) and Herbert et al. 
(1998). Both methods were successfully applied to isolate two proteins of 40 and 43 
kDa which is comparable to the results described by Nieper and Muller (1998). The 
extraction kit, however, produced a higher yield of membrane proteins. Using an 
extraction kit provides many advantages which include expediency, increased 
reproducibility and quality of results (Tan and Yiap, 2009) which could explain the 
higher yield obtained using the extraction kit. Plasma membrane proteins were 
therefore successfully isolated and used in VOPBA experiments. 
 
A VOPBA was used to identify IBDV binding proteins and possible IBDV receptor(s) 
on the plasma membranes isolated from the bursae. The VOPBA has been 
successfully used to identify many virus receptors such as the mouse hepatitis virus 
A59 (Dveksler et al., 1993), porcine epidemic diarrhoea virus (Oh et al., 2003) and 
adenovirus (Trauger et al., 2004). In a conventional VOPBA, whole virus is used to 
probe plasma membranes blotted onto nitrocellulose; therefore the second part of 
the current study required the isolation of IBDV. The virus was successfully purified 
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from infected bursae which was confirmed by the presence of viral proteins VP2, 
VP3 and VP4 at their expected molecular masses. Becht (1994) reported that VP2 
and VP3, the major structural proteins, are present in equal amounts in IBDV 
isolates. This correlates well to the current study as VP2 and VP3 were found to be 
the predominant proteins present in the virus preparation analysed by SDS-PAGE. 
Isolated IBDV was propagated in Vero cells which are derived from normal adult 
African green monkey kidney cells. Cytopathic effects were observed 96 h post-
infection. The IBDV particles were thereafter purified and used in a conventional 
VOPBA. 
 
A conventional VOPBA using IBDV particles and a modified VOPBA using VP2 (the 
receptor binding protein) were performed. In addition, the VOPBA experiments were 
designed to include chicken anti-VP2 antibodies or chicken anti-VP2 peptide 
antibodies. Varying results were obtained for each of the VOPBA experiments. The 
VOPBAs incubated with anti-VP2 peptide antibodies provided inconclusive results 
since the anti-peptide antibodies did not detect any proteins in the plasma 
membrane isolates which IBDV or VP2 specifically bound to. It is unclear why the 
chicken anti-VP2 peptide antibodies did not detect any proteins. One of the 
advantages of using an anti-peptide antibody is that it can be directed to a specific 
target sequence and therefore promote specificity (Adams et al., 1997). This 
advantage, however, can also be seen as a shortfall since only a single epitope in 
the target protein is recognised while an antibody to the whole protein can recognise 
multiple epitopes in a target protein. According to the 3D structure of VP2, the 
epitope recognised by the chicken anti-VP2 peptide antibodies is located on the 
surface and spans amino acids 26 to 39 while the amino acids which are 
responsible for tissue culture adaptation and believed to bind directly with the 
cellular receptor(s) are 253, 279 and 284 (Yip et al., 2007). However, binding of 
chicken anti-VP2 peptide antibodies to VP2 or IBDV depends on how or with which 
orientation they bind to membrane proteins. It is therefore possible that the VOPBAs 
incubated with chicken anti-VP2 peptide antibodies did not detect any proteins 
because IBDV or VP2 epitopes for recognition were not accessible for binding. 
 
The recombinant VP2 specifically bound to a 70 and a 32 kDa protein and IBDV 
specifically bound to a 32 kDa protein which was detected with chicken anti-VP2 
antibodies in a VOPBA. Previous studies have reported the interaction of IBDV with 
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proteins of 70 (Setiyono et al., 2001) and 32 kDa (Edwards, 2000) which is 
comparable to the current study. Setiyono et al. (2001) used a highly virulent strain 
of IBDV propagated in LSCC-BK3 cells and the interaction of IBDV with the 70 kDa 
protein was observed in a VOPBA. In addition to the 70 kDa protein, detection of an 
82 and a 110 kDa protein was reported (Setiyono et al., 2001) which was not 
observed in the current study. The Setiyono et al. (2001) study used plasma 
membranes isolated from LSCC-BK3 cells in a VOPBA whereas the current study 
used plasma membranes isolated from the bursae which may therefore explain the 
different results. Edwards (2000) observed the interaction of IBDV with a 32 kDa 
protein by reversibly cross-linking IBDV to potential receptor molecules on bursal 
cells via 2-iminothiolane. In this method, virus is allowed to bind whole cells via the 
receptor(s) which are then reduced and cross-linked to virus via 2-iminothiolane. 
The cell membranes are disrupted and potential receptor(s) purified using density 
gradient centrifugation. This method of reversibly cross-linking virus to potential 
receptor(s) on cells represents the natural state of viral attachment therefore 
improving the accuracy of the results. 
 
In a study conducted by Nieper and Muller (1996), two proteins of the bursal plasma 
membrane were observed binding to IBDV with molecular masses of 40 and 46 kDa 
in a VOPBA. A 40 and 46 kDa protein was not observed binding to IBDV or VP2 in 
the current study. An attenuated strain of IBDV was used in the Nieper and Muller 
(1996) study, which requires multiple passages before attenuation in CEF cells. 
Tissue culture adaptation and attenuation of IBDV alters amino acid residues in the 
VP2 amino acid sequence (Yamaguchi et al., 1996b, van Loon et al., 2002, Kwon 
and Kim, 2004) which is thought to engage directly with the cellular receptor 
(Coulibaly et al., 2005). The attenuated strain may therefore bind different proteins 
on the surface of plasma membranes compared to the non-attenuated strain of 
IBDV used in the current study and consequently producing different results. 
Although the VOPBA has been successfully used to determine viral receptors (Cao 
et al., 1998a, Li et al., 2003), the method has some limitations. Purified virus is 
required to interact with linearised polypeptides, assuming the interaction between 
virus and protein is non-conformational. Therefore, in addition, affinity purification of 
VP2-binding proteins from bursal plasma membranes was used to confirm and 
compare the results obtained in the VOPBA. 
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The VP2 binding proteins were isolated from bursal plasma membranes using a 
VP2-coupled affinity matrix. Four proteins with molecular masses of 70, 60, 45 and 
32 kDa were purified. Isolation of the 70 and 32 kDa proteins provided positive 
comparable results since proteins with these molecular masses were also detected 
in the VOPBA. In the VOPBA method, the plasma membrane proteins were 
denatured before separation by SDS-PAGE whereas during the affinity purification, 
proteins maintain their conformation. The purification of additional proteins not 
detected in the VOPBA was therefore expected. As previously mentioned, a study 
conducted by Nieper and Muller (1996) reports on the interaction of a 46 kDa protein 
with IBDV which is speculated to be the 45 kDa protein purified in the current study. 
Reports, however, could not be established which describe a 60 kDa IBDV binding 
protein. To identify the proteins, the protein bands in the SDS-PAGE gel were 
excised and in-gel digested with trypsin and the peptides analysed by mass 
spectrometry. The mass spectra were compared with the Uniswiss 2011 protein 
database which identified several peptides common to a few proteins. 
 
A high degree of sequence identity was found with the immunoglobulin (Ig) gamma 
chain of IgY in all the proteins purified. It is unlikely that this was a contamination of 
IgY which was previously purified on the same column (Chapter 2) since the VP2-
column was thoroughly washed and regenerated. A solution of 1 M sodium 
hydroxide was used to clean the column which is commonly used to successfully 
remove proteins bound to chromatography columns (Block, 1991, Hale et al., 1994). 
Although IgY is mainly a circulatory antibody, it has been observed expressed on 
the surface of bursal B cells (Chen et al., 1982, Sharma, 1990) much like its 
mammalian homologue IgG (Lafrenz et al., 1986). IgG and IgY are similar in that 
they both possess two heavy and two light chains, have similar sedimentation 
coefficients of about 7S and play the same biological role of providing defence 
against infectious agents (Larsson et al., 1993). In addition, the Ig gamma chain of 
IgY identified in the current study belongs to the immunoglobulin superfamily. 
Therefore this Ig receptor-like protein represents a good candidate as the IBDV 
receptor(s) since many viruses have been shown to exploit proteins of the 
immunoglobulin superfamily to gain entry into host cells (Dermody et al., 2009, 
Perez et al., 2009). A few examples include CD4, the HIV receptor, which has four 
immunoglobulin domains (Dalgleish et al., 1984), Poliovirus receptor, CD155 which 
has three immunoglobulin domains (Mendelsohn et al., 1989) and the Reovirus 
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receptor, JAM-A which has two immunoglobulin domains (Barton et al., 2001, Prota 
et al., 2003). The chicken B-cell expresses several cell surface proteins which 
belong to the immunoglobulin superfamily such as ICAM-1 which is an adhesion 
molecule which binds B-cells to other cells (Huang and Springer, 1995) and CD80 
which binds to T-cells producing co-stimulatory signals which activate B-cells 
(Peach et al., 1995). Therefore it is hypothesised that this Ig receptor-like protein 
belonging to the immunoglobulin superfamily may possibly form part of the IBDV 
receptor which is expressed on the surface of B-cells. 
 
Peptides of the 60 kDa affinity purified protein also demonstrated sequence identity 
with peptides of the 60 kDa chaperonin of the plant bacterium P. fluorescens while 
the 45 kDa protein demonstrated identity with the 43 kDa elongation factor of Y. 
pestis. These two results were difficult to explain since these are both bacterial 
proteins. Interestingly a study conducted in our laboratory by Edwards (2000) 
reported on a 32 kDa protein observed to interact with IBDV, which demonstrated 
sequence identity with the root adhesin from P. fluorescens. A part of the 32 kDa 
protein’s gene sequence was successfully amplified by PCR and RT-PCR using 
chicken DNA and RNA respectively, which confirmed the protein to be encoded by 
the chicken genome (Edwards, 2000). Similarly, it is suggested that the 60 and 45 
kDa proteins identified in the current study are encoded by the chicken genome 
which has not yet been completely sequenced. In order to test this theory, PCR and 
RT-PCR should be performed on the identified sequences using degenerate 
primers. 
 
The 32 kDa protein identified in the current study shares common peptides with the 
outer major protein of S. marcescens and the Ig lambda chain. Again it is suggested 
that the 32 kDa protein is encoded by the chicken genome and shares common 
peptides with the outer major protein of S. marcescens. Interestingly though, is the 
function of the outer major protein which serves as a receptor for several T-even like 
phages and also acts as a porin (Malouin et al., 1990). The outer major protein 
therefore represents a good candidate as a receptor binding protein although further 
analysis is required to ensure it is a protein which is encoded by the chicken 
genome. Sequence identity of the 32 kDa affinity purified protein to the Ig lambda 
chain further increases the evidence that an Ig receptor-like protein may form part of 
the IBDV receptor. A study conducted by Luo et al. (2010) demonstrated that the 
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lambda light chain of surface IgM specifically interacts with IBDV. This was 
performed by recombinantly expressing the lambda light chain and analysing its 
ability to bind IBDV in a VOPBA (Luo et al., 2010). Therefore it is again observed 
that the 32 kDa protein represents a good candidate as an IBDV receptor or plays a 
role in IBDV entry.  
 
In summary, several proteins have been identified which represent good candidates 
as forming part of the IBDV receptor(s). Further studies are necessary to 
demonstrate and confirm their involvement in IBDV infection which could lead to the 
design and production of antiviral inhibitors which target viral entry. These results 
and any future studies which could be built on from the current study are discussed 
in the following chapter. 
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CHAPTER 4 
GENERAL DISCUSSION 
 
Infectious bursal disease virus (IBDV) is a Birnavirus causing infectious bursal 
disease (IBD), a highly contagious immunosuppressive disease which affects young 
chickens (Kibenge et al., 1988). IBDV infects the immature antibody producing 
B-cells of the bursa of Fabricius (Kibenge et al., 1988), depleting the bursa of B-cells 
as replication of viral particles takes place and bursal cells become atrophic 
(Tanimura and Sharma, 1997, Sharma et al., 2000). Infected chickens, as a result, 
develop a compromised immune system which leaves them susceptible to other 
opportunistic pathogens which in turn increases their mortality rate (Saif, 1991). In 
addition, the disease is highly contagious, resistant to inactivation and spreads 
rapidly through contaminated feed and water (van den Berg et al., 2000). 
Consequently IBD has caused major economic losses in the poultry industry (Muller 
et al., 2003). 
 
The current control strategy for IBD is vaccination (Muller et al., 2012). Although 
there are various IBD vaccines being used such as subunit vaccines, IBDV immune 
complex vaccines and live viral vector vaccines, the success of the vaccines is 
dependent on various factors. These include presence of maternally derived 
antibodies, the age of chickens and time period during which vaccination is 
administered, vaccination strains and epidemiological field conditions 
(Rautenschlein et al., 2005). Maternally derived antibodies in young chickens 
(Corley and Giambrone, 2002) and the continuous emergence of new virulent IBDV 
strains (Cao et al., 1998b) limit vaccine effectiveness and in addition some vaccines 
have been shown to cause moderate to severe bursal atrophy (Rautenschlein et al., 
2005). Therefore it is important to focus on new strategies to control the disease.  
 
Virus attachment to receptor proteins, which assist in entry into host cells, is a 
critical step in the virus life cycle (Smith and Helenius, 2004). Development of 
antiviral agents which inhibit entry is a novel alternative strategy to control the 
disease.  The identity of the receptor binding proteins of the virus and the receptors 
on target cells are required for the development of antiviral agents. Viral entry, 
however, of many non-enveloped viruses is at present not fully resolved as it is a 
complex process which utilises penetration to gain access into host cells. Virus must 
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first initiate interaction with receptor(s) and/or co-receptor(s) which activates a series 
of events which ultimately allows successful infection of host cells. Therefore, in 
order to produce antiviral agents which target viral entry, in depth knowledge of 
receptor(s) and/or co-receptor(s) and the comprehensive understanding of the virus 
mechanism of entry is required. VP2 is the receptor binding protein of IBDV (Yip et 
al., 2007), however, the receptor(s) on B-cells used for IBDV entry have not been 
identified although various studies have been conducted. Nieper and Muller (1996) 
demonstrated the ability of attenuated IBDV to bind a 40 and 46 kDa protein on CEF 
cells and Ogawa et al. (1998) reported that the IBDV receptor is an N-glycosylated 
protein associated with the expression of B-cell surface IgM. Later, Setiyono et al. 
(2001) demonstrated a very virulent strain of IBDV binding to three proteins with 
molecular masses of 70, 80 and 110 kDa on LSCC-BK3 cells while Lin et al. (2007) 
reported that chicken heat shock protein 90 (Hsp90) forms part of and is required for 
IBDV entry into DF-1 cells. Although extensive research has been conducted on 
identifying the IBDV receptor(s), it is yet to be conclusively determined. 
 
The aim of this study was to determine possible IBDV receptors on host cells of the 
bursa of Fabricius by different experimental techniques through the use of the 
receptor binding protein, VP2. Previous studies used different IBDV susceptible cell 
lines to assist in identifying the IBDV receptor(s). Susceptible cells used were CEF 
cells (Nieper and Muller, 1996, Ogawa et al., 1998), LSCC-BK3 cells (Setiyono et 
al., 2001) and DF-1 cells (Lin et al., 2007). The current study, however, used a 
different approach. Plasma membrane proteins from the bursa of Fabricius and 
VP2, the receptor binding protein, were used. First, a conventional and modified 
VOPBA incubated with IBDV or VP2 respectively was used with either chicken anti-
VP2 antibodies or chicken anti-VP2 peptide antibodies to determine IBDV binding 
proteins. Secondly VP2-binding proteins from the bursal plasma membrane were 
affinity purified on a VP2-coupled affinity matrix and analysed by mass 
spectrometry. To do this the VP2 protein was recombinantly expressed, affinity 
purified and used to prepare a VP2-coupled affinity matrix. In addition recombinant 
VP2 and peptides identified from the VP2 amino acid sequence were used to raise 
polyclonal chicken anti-VP2 antibodies and chicken anti-VP2 peptide antibodies to 
assist in identifying IBDV binding proteins in a virus overlay protein binding assay 
(VOPBA). 
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Since the main aim required the use of VP2 to assist in identifying the IBDV 
receptor(s), large quantities of recombinant VP2 was required. The VP2 coding 
sequence was previously cloned into pGEX-4T-1 and pET-32a expression vectors 
and transformed into E. coli cells in our laboratory. Therefore expression of the VP2 
protein was attempted in the E. coli expression systems. Auto-induced expression of 
VP2 using the pET-32a E. coli expression system was successful since VP2 
expressed as a 64 kDa and a high molecular mass His-tagged protein. The high 
molecular mass proteins were believed to be VP2 after mouse anti-His tag 
monoclonal antibody and later, chicken anti-VP2 antibodies detected them in a 
western blot. Furthermore, reduction of the high molecular mass proteins and 
analysis by reducing SDS-PAGE after electro-elution saw the proteins run as a 64 
kDa protein band (the expected size of the VP2 fusion protein), as well as towards 
the top of the gel. Expression of VP2 in the pET-32a E. coli  system, however, 
expressed as insoluble inclusion bodies despite subsequent decreases in 
expression temperature which is known to increase solubility of expressed protein 
(Schein and Noteborn, 1988). Purification of large enough quantities of the insoluble 
VP2 was a difficult task. Affinity chromatography of recombinant VP2 via the His-tag 
under denaturing conditions saw VP2 co-purify with other contaminating bacterial 
proteins. In addition purification under denaturing conditions was considered 
unfavourable since correctly folded VP2 was required for preparation of a VP2-
coupled affinity matrix. On-column refolding of recombinant VP2 also via the His-tag 
was therefore preferred and was successfully used to purify recombinant VP2. 
Purification though produced low yields of pure recombinant VP2 and large amounts 
were observed in the unbound and wash fractions during on-column refolding. The 
wash fractions containing VP2 were therefore retained and VP2 successfully purified 
from these samples using ion-exchange chromatography. Since purifying large 
enough yields of recombinant VP2 was difficult alternative expression systems were 
considered. 
 
The Pichia pastoris yeast expression system was considered a favourable option 
since expressed proteins are predominantly secreted allowing for ease of 
purification. Additionally, VP2 has been previously expressed in this system 
(Pitcovski et al., 1996, Wu et al., 2005, Villegas et al., 2008). The VP2 coding 
sequence was therefore sub-cloned into the pPIC9 expression vector and integrated 
into the P. pastoris genome. The VP2 protein was successfully expressed as a 
47 kDa and high molecular mass protein which was concentrated and purified using 
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three-phase partitioning. Molecular exclusion chromatography was used to further 
purify VP2 from contaminating proteins and successfully separated the high 
molecular mass VP2, but not the 47 kDa VP2 from other proteins. Large enough 
yields of purified recombinant VP2 in the form of incorrectly folded or high molecular 
mass proteins was therefore obtained for further use. Although the high molecular 
mass proteins were sufficiently detected by chicken anti-VP2 peptide and chicken 
anti-VP2 antibodies to identify them as VP2 proteins, sequencing of the recombinant 
protein for further identification was not carried out. Sequencing of the high 
molecular mass proteins could further corroborate and confirm this observable 
result. Recombinant VP2 expressed in the E. coli expression system was used to 
raise polyclonal chicken anti-VP2 antibodies while VP2 expressed in the P. pastoris 
expression system was used to produce a VP2-coupled affinity matrix for the 
purification of chicken anti-VP2 antibodies and VP2-binding proteins of the bursal 
plasma membrane. Additionally two peptides were selected for the production of 
chicken anti-VP2 peptide antibodies. The idea was to compare and determine the 
chicken anti-VP2 and chicken anti-VP2 peptide antibodies’ ability to bind VP2 or 
IBDV in a VOPBA. 
 
Polyclonal chicken anti-VP2 antibodies were successfully produced as evidenced by 
the high antibody titres obtained which therefore suggests the recombinant VP2 is 
able to maintain its immunogenic properties as native VP2. Although comparably 
low antibody titres were observed for antibodies produced against one of the 
peptides (CKMVATAbuDSSDR)), antibodies against a second peptide 
(ASIPDDTLEKHTLRC) were relatively high and therefore, overall, chicken 
antibodies were successfully produced against recombinant VP2 and against a 
peptide. To determine IBDV-binding proteins in a conventional and modified 
VOPBA, plasma membrane proteins were isolated from the bursa of Fabricius of 
healthy chickens and IBDV was isolated from the bursa of Fabricius of IBDV 
infected chickens. The isolated IBDV was propagated in Vero cells and purified for 
use in a conventional VOPBA while recombinant VP2 was used in a modified 
VOPBA. Chicken anti-VP2 antibodies or chicken anti-VP2 peptide antibodies were 
used to detect IBDV-binding proteins and possible IBDV receptor(s). In addition, 
VP2 binding proteins and possible IBDV receptor(s) of the bursal plasma 
membranes were affinity purified on a VP2-coupled affinity matrix and identified 
using mass spectrometry. 
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The findings presented here are comparable with previous studies, however, new 
data was obtained which offers further insight into the identity of the IBDV 
receptor(s). Given that this study used recombinant VP2 and plasma membrane 
proteins of the bursa of Fabricius, novel interactions were expected. Four IBDV-
binding proteins were identified which may represent the putative receptor(s) and/or 
co-receptor(s) for IBDV. The most significant IBDV binding proteins identified in the 
current study were two proteins with molecular masses of 70 and 32 kDa. In both 
the affinity purification and VOPBA experiments a 70 and a 32 kDa protein was 
purified and binding of VP2 and IBDV observed. Interestingly, a study conducted by 
Setiyono et al. (2001) reports that a 70 kDa plasma membrane protein of LSCC-BK3 
cells specifically bound to IBDV in a VOPBA. Moreover, a study conducted 
previously in our laboratory reports that a 32 kDa protein was observed interacting 
with IBDV by reversibly cross-linking IBDV to potential receptor molecules on bursal 
cells via 2-iminothiolane (Edwards, 2000). Therefore the results of the present study 
are in agreement with those of previous reports. No additional proteins were 
observed binding in the VOPBA experiments while affinity purification of VP2-
binding proteins of the bursal plasma membrane also produced a 60 and a 45 kDa 
protein. Setiyono et al. (2001) also reported that a 82 and a 110 kDa plasma 
membrane protein bound to IBDV in the VOPBA which was not observed in the 
present study, however, a study conducted by Nieper and Muller (1996) reported 
that IBDV bound to two proteins of 40 and 46 kDa on bursal plasma membranes. 
Here we speculate that the 45 kDa protein purified in the current study may be the 
46 kDa protein identified by Nieper and Muller (1996). Tandem mass spectrometry 
was performed on the four affinity purified proteins to assist in further identification of 
these VP2 binding proteins and possible IBDV receptor(s). 
 
Mass spectrometry analysis identified a diverse group of proteins which share 
common peptides with the affinity purified proteins. These proteins included the Ig-
gamma chain of IgY, the Ig-lambda chain, outer major protein of S. marcescens, the 
60 kDa chaperonin of P. fluorescens and elongation factor-Tu of Y. pestis. 
Identification of the Ig gamma-chain (belonging to the immunoglobulin superfamily) 
suggest that IgY is a potential candidate as the IBDV receptor. This is a plausible 
theory since many viruses have been shown to exploit proteins of the 
immunoglobulin superfamily to gain entry into host cells such as the rhinovirus which 
exploits ICAM-1 (five immunoglobulin domains) to gain access into respiratory 
epithelial cells (Tomassini et al., 1989, Dermody et al., 2009) and HIV which exploits 
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CD4 (four immunoglobulin domains) to gain access into T-cells (Dalgleish et al., 
1984, Dermody et al., 2009). In addition, although IgY is identified mainly as a 
circulatory antibody, a small percentage of bursal B-cells express surface IgY (Chen 
et al., 1982, Sharma, 1990). Interestingly, some bursal B-cells which are IgY+ 
express surface IgM (Kincade and Cooper, 1971, Chen and Cooper, 1987) and it is 
believed that surface IgM-bearing B-cells are the target cells for IBDV infection (Hirai 
and Calnek, 1979, Ogawa et al., 1998). Therefore, overall, IgY is a good candidate 
as the receptor/co-receptor of IBDV. The Ig-lambda chain of IgM has been shown to 
specifically interact with IBDV in a VOPBA (Luo et al., 2010), therefore identifying 
the Ig-lambda chain is in agreement with previous studies. 
 
Mass spectrometry analysis also identified bacterial proteins which have common 
peptides with the four affinity purified proteins. Although the chicken genome has 
been extensively studied and drafts of the genome sequence have been presented 
(ICGSC, 2004) several genes have not been annotated. It is therefore likely that the 
proteins identified in the current study do in fact belong to the chicken genome. 
What is interesting about outer major protein of S. marcescens is that it is a 
membrane protein and functions as a cell surface receptor for T-even like phages 
(Braun and Cole, 1984). The 60 kDa chaperonin of P. fluorescens and elongation 
factor-Tu of Y. pestis, however, are not membrane bound proteins and their 
functions are to promote the correct folding of polypeptides and assist in peptide 
bond synthesis respectively. Further investigation is therefore required to determine 
if the bacterial proteins identified do in fact belong to the chicken genome and once 
this is established, their role in IBDV entry can be further resolved. 
 
Various studies can be developed from the data and sequence identities obtained in 
the current study. First, since IgY was identified as a possible receptor for IBDV 
infection, cloning and recombinantly expressing the Ig-gamma chain of IgY and 
analysing its ability to bind IBDV in a VOPBA could further elucidate this notion. 
Furthermore, since the sequences of the proteins have been identified, anti-peptide 
antibodies or monoclonal antibodies against the peptide sequences can be 
produced and used in cell culture to determine their ability to inhibit IBDV entry. 
Second, a study is required which can determine whether the bacterial proteins 
identified are in fact proteins which belong to the chicken genome. Successful PCR 
and RT-PCR of the identified peptides using chicken DNA or RNA degenerate 
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primers would provide supportive evidence. Once this is established, their roles as 
an IBDV receptor or co-receptor can be further determined. 
 
In conclusion, utilising the receptor binding protein, VP2 to identify IBDV-binding 
proteins was successfully achieved. Four potential proteins were identified using 
VOPBA experiments and affinity chromatography which were further characterised 
by mass spectrometry. The results obtained from the current study provide a basis 
from which to work on in identifying the IBDV receptor(s). Taken as a whole, 
identifying the proteins in this study as the IBDV receptor will help in the design and 
production of antiviral agents which target and obstruct IBDV entry into bursal B-
cells and therefore assist in the control of IBDV infection. 
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APPENDIX 
Peptide sequences identified by mass spectrometry 
 
Table 1 Peptide sequences of the 70 kDa affinity purified protein 
Protein Identified Homologous Peptide Sequences 
Ig gamma chain 
SFVCSAAPGGALLK 
VDPVPPVAPEVQVLH 
AIPPSPGELYISLDAK 
SAVPVSTQDWLSGER 
TVQHEELPLPLSK 
NTGPTTPPLIYPFAPHPEELSLSR 
AVPATEFVTTAVLPEERTANGAGGDGDTFFVYSK 
 
 
Table 2 Peptide sequences of the 60 kDa affinity purified protein 
Protein Detected Homologous Peptide Sequences 
Ig gamma chain 
GHGTEVIVSSASPTSPPR 
SFVCSAAPGGALLK 
VDPVPPVAPEVQVLH 
SAEVEWLVDGVGGLLVASQSPAVR 
VNVSGTDWR 
VRHPATNTVVEDHVK 
AIPPSPGELYISLDAK 
SGNLRPDPM 
SAVPVSTQDWLSGER 
AVPATEFVTTAVLPEER 
60 kDa chaperonin (Protein Cpn60) (groEL 
protein) 
AVAAGMNPMDLK 
EMLPVLEAVAK 
SALQAASSIGGLILTTEAAVADAPK 
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Table 3 Peptide sequences of the 45 kDa affinity purified protein 
Protein Detected Homologous Peptide Sequences 
Ig gamma chain 
GTEVIVSSASPTSPPR 
SAAPGGALLK 
SPASAEVEWLVDGVGGLLVASQSPAVR 
AVPATEFVTTAVLPEERTANGAGGDGDTFFVYSK 
Elongation factor - Tu 
ELLSAYDFPGDDLPVVR 
ALEGEAEWEAK 
  AIDKPFLLPIEDVFSISGR 
  VGEEVEIVGIK 
  AGENVGVLLR 
 
 
Table 4 Peptide sequences of the 32 kDa affinity purified protein 
Protein Detected Homologous Peptide Sequences 
Ig gamma chain 
VSGTPVKLSFVR 
VRHPATNTVVEDHVK 
AVPATEFVTTAVLPEER 
Immunoglobulin lambda 
chain 
ALTQPASVSANLGGTVK 
SPGSAPVTVIYDNDKR 
  SDVLFNFNK 
Outer major protein AEGQQALDQLYTQLSSMDPKDGSVVVLGYTDAVGSDQYNQK 
  AQSVVDYLVSK 
  GIKDVVTQPQG 
 
 
